Intellipharmaceutics International (IPCIF) 20-F/A 4 Mar 19 2018 FY Annual report (foreign) (amended) Financial data

Document And Entity Information

Document And Entity Information - CAD ($)	12 Months Ended
	Nov. 30, 2018	Feb. 14, 2019	May 31, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	Intellipharmaceutics International Inc.
Trading Symbol	ipci
Document Type	20-F
Current Fiscal Year End Date	--11-30
Entity Common Stock, Shares Outstanding		0
Entity Public Float			$ 0
Amendment Flag	false
Entity Central Index Key	1,474,835
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Well-known Seasoned Issuer	No
Document Period End Date	Nov. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	FY

Consolidated Balance Sheets

Consolidated Balance Sheets - CAD ($)	Nov. 30, 2018	Nov. 30, 2017
Current
Cash	$ 6,641,877	$ 1,897,061
Accounts receivable, net (Note 4)	239,063	689,619
Investment tax credits	998,849	636,489
Prepaid expenses, sundry and other assets	586,794	225,092
Inventory (Note 3)	251,651	115,667
Current Assets	8,718,234	3,563,928
Deferred offering costs (Note 10)	0	565,302
Property and equipment, net (Note 5)	2,755,993	3,267,551
Assets	11,474,227	7,396,781
Current
Accounts payable	2,643,437	2,060,084
Accrued liabilities (Note 6)	353,147	782,369
Employee costs payable (Note 8)	222,478	214,980
Convertible debentures (Note 7)	1,790,358	1,290,465
Deferred revenue (Note 3)	300,000	300,000
Current Liabilities	5,309,420	4,647,898
Deferred revenue (Note 3)	2,062,500	2,362,500
Liabilities	7,371,920	7,010,398
Shareholders' equity
Capital stock (Note 10) authorized, unlimited common shares without par value, unlimited preference shares issued and outstanding 18,252,243 common shares (November 30, 2017 - 3,470,451)	44,327,952	35,290,034
Additional paid-in capital	45,110,873	36,685,387
Accumulated other comprehensive income	284,421	284,421
Accumulated deficit	(85,620,939)	(71,873,459)
Stockholders' Equity	4,102,307	386,383
Contingencies (Note 16)
Liabilities and Stockholders' Equity	$ 11,474,227	$ 7,396,781

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - shares	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017
Statement of Financial Position [Abstract]
Common shares, Authorized	Unlimited	Unlimited
Common shares, Issued	18,252,243	3,470,451
Common shares, Outstanding	18,252,243	3,470,451

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss	12 Months Ended
	Nov. 30, 2018$ / shares	Nov. 30, 2018CAD ($)shares	Nov. 30, 2017$ / shares	Nov. 30, 2017CAD ($)shares	Nov. 30, 2016$ / shares	Nov. 30, 2016CAD ($)shares
Revenues
Licensing (Note 3)		$ 1,370,607		$ 5,025,350		$ 2,209,502
Up-front fees (Note 3)		342,124		479,102		37,500
Revenues		1,712,731		5,504,452		2,247,002
Cost of good sold
Cost of goods sold		124,870		704,006		0
Gross Margin		1,587,861		4,800,446		2,247,002
Expenses
Research and development		10,827,293		9,271,353		8,166,736
Selling, general and administrative		3,476,450		3,287,914		3,546,132
Depreciation (Note 5)		610,384		506,961		385,210
Expenses		14,914,127		13,066,228		12,098,078
Loss from operations		(13,326,266)		(8,265,782)		(9,851,076)
Net foreign exchange (loss) gain		8,592		(80,093)		(22,470)
Interest income		227		15,037		207
Interest expense		(255,231)		(389,239)		(270,238)
Financing cost (Note 10)		(174,802)		(137,363)		0
Net loss and comprehensive loss		$ (13,747,480)		$ (8,857,440)		$ (10,143,577)
Loss per common share, basic and diluted | $ / shares	$ (2.89)		$ (2.86)		$ (3.80)
Weighted average number of common shares outstanding, basic and diluted | shares		4,762,274		3,101,448		2,669,958

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity (Deficiency) - CAD ($)	Capital Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Beginning balance at Nov. 30, 2015	$ 21,481,242	$ 30,969,093	$ 284,421	$ (52,872,442)	$ (137,686)
Balance, shares at Nov. 30, 2015	24,244,050
Share issuance cost (Note 10)	$ (1,002,655)	(158,736)			(1,161,391)
Stock options to employees		2,261,444			2,261,444
DSU's to non-management board members		31,628			31,628
Shares issued for options exercised (Note 11)	$ 87,259	(34,391)			$ 52,868
Shares issued for options exercised (Note 11), shares	2,750				(2,750)
Proceeds from at-the-market financing (Note 10)	$ 3,469,449				$ 3,469,449
Proceeds from at-the-market financing (Note 10), shares	147,126
Proceeds from issuance of shares and warrants (Note 10 & 14)	$ 4,764,777	1,175,190			5,939,967
Proceeds from issuance of shares and warrants (Note 10 & 14), shares	368,927
Issuance of shares on exercise of warrants (Note 14)	$ 1,030,719	(330,066)			700,653
Issuance of shares on exercise of warrants (Note 14), shares	35,791
Modification of convertible debt (Note 7)		102,909			102,909
Net loss				(10,143,577)	(10,143,577)
Ending balance at Nov. 30, 2016	$ 29,830,791	34,017,071	284,421	(63,016,019)	1,116,264
Balance, shares at Nov. 30, 2016	2,978,999
Share issuance cost (Note 10)		(685,319)	(108,912)		(794,231)
Stock options to employees		1,749,999			1,749,999
DSU's to non-management board members		30,355			30,355
Shares issued for options exercised (Note 11)	$ 1,100	642			$ 1,742
Shares issued for options exercised (Note 11), shares	200				200
Proceeds from at-the-market financing (Note 10)	$ 2,541,640				$ 2,541,640
Proceeds from at-the-market financing (Note 10), shares	110,815
Proceeds from issuance of shares and warrants (Note 10 & 14)	$ 3,257,445	742,555			4,000,000
Proceeds from issuance of shares and warrants (Note 10 & 14), shares	363,636
Cost of warrants issued to placement agent (Note 14)		(86,196)	86,196		0
Issuance of shares on exercise of warrants (Note 14)	$ 430,573	(106,315)			324,258
Issuance of shares on exercise of warrants (Note 14), shares	16,801
Modification of convertible debt (Note 7)		273,796			273,796
Net loss				(8,857,440)	(8,857,440)
Ending balance at Nov. 30, 2017	$ 35,290,034	36,685,387	284,421	(71,873,459)	386,383
Balance, shares at Nov. 30, 2017	3,470,451
Share issuance cost (Note 10)	$ (736,652)	(2,568,321)			(3,304,973)
Stock options to employees		927,686			927,686
DSU's to non-management board members		7,565			$ 7,565
Shares issued for options exercised (Note 11), shares
Proceeds from issuance of shares and warrants (Note 10 & 14)	$ 5,993,472	13,651,434			$ 19,644,906
Proceeds from issuance of shares and warrants (Note 10 & 14), shares	3,658,564
Proceeds from exercise of Pre-Funded Warrants (Note 14)	$ 4,012,528	(3,901,275)			111,253
Proceeds from exercise of Pre-Funded Warrants (Note 14), shares	11,123,334
Shares to be issued from exercise of Pre-Funded Warrants (Note 10 & 14)	$ 371,551	(361,251)			10,300
Cost of warrants issued to placement agent (Note 14)	$ (602,981)	602,981
Issuance of shares on exercise of warrants (Note 14)		0			0
Beneficial conversion feature related to convertible debenture (Note 7)		66,667			66,667
Net loss				(13,747,480)	(13,747,480)
Rounding of fractional shares after consolidation (Note 2)	(106)
Ending balance at Nov. 30, 2018	$ 44,327,952	$ 45,110,873	$ 284,421	$ (85,620,939)	$ 4,102,307
Balance, shares at Nov. 30, 2018	18,252,243

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - CAD ($)	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2016
Statement of Cash Flows [Abstract]
Net loss	$ (13,747,480)	$ (8,857,440)	$ (10,143,577)
Items not affecting cash
Depreciation (Note 5)	612,736	520,838	385,210
Stock-based compensation (Note 11)	927,686	1,749,999	2,261,444
Deferred share units (Note 12)	7,565	30,355	31,628
Accreted interest (Note 7)	66,560	219,497	79,245
Financing cost (Note 10)	174,802	137,363	0
Provision for doubtful debts (Note 4)	0	66,849	0
Unrealized foreign exchange loss (gain)	52,613	56,998	22,916
Change in non-cash operating assets & liabilities
Accounts receivable	450,556	(283,994)	6,200
Investment tax credits	(362,360)	44,647	(223,115)
Prepaid expenses, sundry and other assets	(361,702)	175,550	(171,417)
Inventory	(135,984)	(115,667)	0
Accounts payable, accrued liabilities and employee costs payable	106,048	599,220	(1,466,019)
Deferred revenue	(300,000)	(450,000)	2,962,500
Cash flows used in operating activities	(12,508,960)	(6,105,785)	(6,254,985)
Financing activities
Repayment of convertible debenture (Note 7)	0	(150,000)	0
2018 Debenture financing (Note 7)	500,000	0	0
Repayment of capital lease obligations	0	(14,829)	(21,291)
Issuance of shares on exercise of stock options (Note 11)	0	1,742	52,868
Issuance of common shares on at-the-market financing, gross (Note 10)	0	2,541,640	3,469,449
Proceeds from issuance of shares and warrants, gross (Note 10)	19,644,906	4,000,000	5,939,967
Proceeds from issuance of shares on exercise of warrants (Note 14)	111,253	324,258	700,653
Proceeds from shares to be issued from exercise of Pre-Funded Warrants (Note 14)	10,300	0	0
Offering costs	(2,911,505)	(1,020,643)	(982,023)
Cash flows provided from financing activities	17,354,954	5,682,168	9,159,623
Investing activity
Purchase of property and equipment (Note 5)	(101,178)	(1,823,746)	(515,410)
Cash flows used in investing activities	(101,178)	(1,823,746)	(515,410)
Increase (decrease) in cash	4,744,816	(2,247,363)	2,389,228
Cash, beginning of year	1,897,061	4,144,424	1,755,196
Cash, end of year	6,641,877	1,897,061	4,144,424
Supplemental cash flow information
Interest paid	209,675	123,204	165,585
Taxes paid	$ 0	$ 0	$ 0

Note 1 - Nature of Operations

Note 1 - Nature of Operations	12 Months Ended
	Nov. 30, 2018
Disclosure Text Block [Abstract]
Nature of Operations	Intellipharmaceutics International Inc. (“IPC” or the “Company”) is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. On October 22, 2009, IntelliPharmaCeutics Ltd. (“IPC Ltd. “) and Vasogen Inc. (“Vasogen”) completed a court approved plan of arrangement and merger (the “IPC Arrangement Agreement”), resulting in the formation of the Company, which is incorporated under the laws of Canada. The Company’s common shares are traded on the Toronto Stock Exchange (“TSX”) and the Nasdaq Capital Market (“Nasdaq”). The Company earns revenue from non-refundable upfront fees, milestone payments upon achievement of specified research or development, exclusivity milestone payments and licensing and cost plus payments on sales of resulting products. In November 2013, the U.S. Food and Drug Administration (“FDA”) granted the Company final approval to market the Company’s first product, the 15 mg and 30 mg strengths of the Company’s generic Focalin XR® (dexmethylphenidate hydrochloride extended-release) capsules. In 2017, the FDA granted final approval for the remaining 6 (six) strengths, all of which have been launched. In May 2017, the FDA granted the Company final approval for its second commercialized product, the 50, 150, 200, 300 and 400 mg strengths of generic Seroquel XR® (quetiapine fumarate extended release) tablets, and the Company commenced shipment of all strengths that same month. In November 2018, the FDA granted the Company final approval for its venlafaxine hydrochloride extended-release capsules in the 37.5, 75, and 150 mg strengths. Going concern The consolidated financial statements are prepared on a going concern basis, which assumes that the Company will be able to meet its obligations and continue its operations for the next twelve months. The Company has incurred losses from operations since inception and has reported losses of $13,747,480 for the year ended November 30, 2018 (2017 - $8,857,440; 2016 - $10,143,577), and has an accumulated deficit of $85,620,939 as at November 30, 2018 (November 30, 2017 - $71,873,459). The Company has a working capital of $3,408,814 as at November 30, 2018 (November 30, 2017 – working capital deficiency of $1,083,970). The Company has funded its research and development (“R&D”) activities principally through the issuance of securities, loans from related parties, funds from the IPC Arrangement Agreement, and funds received under development agreements. There is no certainty that such funding will be available going forward. These conditions raise substantial doubt about its ability to continue as a going concern and realize its assets and pay its liabilities as they become due. In order for the Company to continue as a going concern and fund any significant expansion of its operation or R&D activities, the Company may require significant additional capital. Although there can be no assurances, such funding may come from revenues from the sales of the Company’s generic Focalin XR® (dexmethylphenidate hydrochloride extended-release) capsules, from revenues from the sales of the Company’s generic Seroquel XR® (quetiapine fumarate extended-release) tablets and from potential partnering opportunities. Other potential sources of capital may include payments from licensing agreements, cost savings associated with managing operating expense levels, other equity and/or debt financings, and/or new strategic partnership agreements which fund some or all costs of product development. The Company’s ultimate success will depend on whether its product candidates receive the approval of the FDA or Health Canada and whether it is able to successfully market approved products. The Company cannot be certain that it will be able to receive FDA or Health Canada approval for any of its current or future product candidates, or that it will reach the level of sales and revenues necessary to achieve and sustain profitability, or that the Company can secure other capital sources on terms or in amounts sufficient to meet its needs. The availability of equity or debt financing will be affected by, among other things, the results of the Company’s R&D, its ability to obtain regulatory approvals, its success in commercializing approved products with its commercial partners and the market acceptance of its products, the state of the capital markets generally, strategic alliance agreements, and other relevant commercial considerations. In addition, if the Company raises additional funds by issuing equity securities, its then existing security holders will likely experience dilution, and the incurring of indebtedness would result in increased debt service obligations and could require the Company to agree to operating and financial covenants that would restrict its operations. Any failure on its part to successfully commercialize approved products or raise additional funds on terms favorable to the Company or at all, may require the Company to significantly change or curtail its current or planned operations in order to conserve cash until such time, if ever, that sufficient proceeds from operations are generated, and could result in the Company not taking advantage of business opportunities, in the termination or delay of clinical trials or the Company not taking any necessary actions required by the FDA or Health Canada for one or more of the Company’s product candidates, in curtailment of the Company’s product development programs designed to identify new product candidates, in the sale or assignment of rights to its technologies, products or product candidates, and/or its inability to file Abbreviated New Drug Applications (“ANDAs”), Abbreviated New Drug Submissions (“ANDSs”) or New Drug Applications (“NDAs”) at all or in time to competitively market its products or product candidates. The consolidated financial statements do not include any adjustments that might result from the outcome of uncertainties described above. If the going concern assumption no longer becomes appropriate for these consolidated financial statements, then adjustments would be necessary to the carrying values of assets and liabilities, the reported expenses and the balance sheet classifications used. Such adjustments could be material.

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	12 Months Ended
	Nov. 30, 2018
Disclosure Text Block [Abstract]
Basis of Presentation	(a) Basis of consolidation These consolidated financial statements include the accounts of the Company and its wholly owned operating subsidiaries, IPC Ltd., Intellipharmaceutics Corp. (“IPC Corp”), and Vasogen Corp. References in these consolidated financial statements to share amounts, per share data, share prices, exercise prices and conversion rates have been adjusted to reflect the effect of the 1-for-10 reverse split which became effective on each of Nasdaq and TSX at the opening of the market on September 14, 2018. In September 2018, the Company announced a one-for-ten share consolidation (the “reverse split”). At a special meeting of the Company’s shareholders held on August 15, 2018, the Company’s shareholders granted the Company’s Board of Directors discretionary authority to implement a consolidation of the issued and outstanding common shares of the Company on the basis of a consolidation ratio within a range from five (5) pre-consolidation common shares for one (1) post-consolidation common share to fifteen (15) pre-consolidation common shares for one (1) post-consolidation common share. The Board of Directors selected a share consolidation ratio of ten (10) pre-consolidation shares for one (1) post-consolidation common share. On September 12, 2018, the Company filed an amendment to the Company’s articles ("Articles of Amendment") to implement the one-for-10 reverse split. The Company’s common shares began trading on each of the Nasdaq and TSX on a post-split basis under the Company’s existing trade symbol "IPCI" at the opening of the market on September 14, 2018. In accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), the change has been applied retroactively. All inter-company accounts and transactions have been eliminated on consolidation. (b) Use of estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the year. Actual results could differ from those estimates. Areas where significant judgment is involved in making estimates are: the determination of the functional currency; the fair values of financial assets and liabilities; the determination of units of accounting for revenue recognition; the accrual of licensing and milestone revenue; and forecasting future cash flows for assessing the going concern assumption.

Note 3 - Significant Accounting

Note 3 - Significant Accounting Policies	12 Months Ended
	Nov. 30, 2018
Accounting Policies [Abstract]
Significant Accounting Policies	(a) Cash and cash equivalents The Company considers all highly liquid securities with an original maturity of three months or less to be cash equivalents. Cash equivalent balances consist of bankers’ acceptances and bank accounts with variable market rates of interest. The financial risks associated with these instruments are minimal and the Company has not experienced any losses from investments in these securities. The carrying amount of cash approximates its fair value due to its short-term nature. As at November 30, 2018 and 2017, the Company had no cash equivalents. (b) Accounts receivable The Company reviews its sales and accounts receivable aging and determines whether an allowance for doubtful accounts is required. (c) Financial instruments The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are classified as liabilities, the derivative instrument is initially recorded at its fair value using the appropriate valuation methodology and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations and comprehensive loss. (d) Investment tax credits The investment tax credits (“ITC") receivable are amounts considered recoverable from the Canadian federal and provincial governments under the Scientific Research & Experimental Development (“SR&ED”) incentive program. The amounts claimed under the program represent the amounts based on management estimates of eligible research and development costs incurred during the year. Realization is subject to government approval. Any adjustment to the amounts claimed will be recognized in the year in which the adjustment occurs. Refundable ITCs claimed relating to capital expenditures are credited to property and equipment. Refundable ITCs claimed relating to current expenditures are netted against research and development expenditures. (e) Property and equipment Property and equipment are recorded at cost. Equipment acquired under capital leases are recorded net of imputed interest, based upon the net present value of future payments. Assets under capital leases are pledged as collateral for the related lease obligation. Repairs and maintenance expenditures are charged to operations; major betterments and replacements are capitalized. Depreciation bases and rates are as follows: Assets Basis Rate Computer equipment Declining balance 30% Computer software Declining balance 50% Furniture and fixtures Declining balance 20% Laboratory equipment Declining balance 20% Leasehold improvements Straight line Over term of lease Leasehold improvements and assets acquired under capital leases are depreciated over the term of their useful lives or the lease period, whichever is shorter. The charge to operations resulting from depreciation of assets acquired under capital leases is included with depreciation expense. (f) Impairment of long-lived assets Long-lived assets are reviewed for impairment when events or circumstances indicate that the carrying value of an asset may not be recoverable. For assets that are to be held and used, impairment is recognized when the sum of estimated undiscounted cash flows associated with the asset or group of assets is less than its carrying value. If impairment exists, an adjustment is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value. (g) Warrants The Company previously issued warrants as described in Notes 10 and 14. In fiscal 2013, the outstanding warrants were presented as a liability because they did not meet the criteria of Accounting Standard Codification (“ASC”) topic 480 Distinguishing Liabilities from Equity for equity classification. Subsequent changes in the fair value of the warrants were recorded in the consolidated statements of operations and comprehensive loss. The Company changed its functional currency effective December 1, 2013 such that these warrants met the criteria for prospective equity classification in ASC topic 480, and the U.S. dollar translated amount of the warrant liability at December 1, 2013 became the amount reclassified to equity. (h) Convertible debentures In fiscal 2013, the Company issued an unsecured convertible debenture in the principal amount of $1.5 million (the “2013 Debenture”) as described in Note 7. At issuance, the conversion option was bifurcated from its host contract and the fair value of the conversion option was characterized as an embedded derivative upon issuance as it met the criteria of ASC topic 815 Derivatives and Hedging. Subsequent changes in the fair value of the embedded derivative were recorded in the consolidated statements of operations and comprehensive loss. The proceeds received from the 2013 Debenture less the initial amount allocated to the embedded derivative were allocated to the liability and were accreted over the life of the 2013 Debenture using the effective rate of interest. The Company changed its functional currency effective December 1, 2013 such that the conversion option no longer met the criteria for bifurcation and was prospectively reclassified to shareholders’ equity under ASC Topic 815 at the U.S. dollar translated amount at December 1, 2013. On September 10, 2018, the Company completed a private placement financing of an unsecured convertible debenture in the principal amount of $0.5 million (the “2018 Debenture”) as described in Note 7. At issuance, the conversion price was lower than the market share price, and the value of the beneficial conversion feature related to the 2018 Debenture was allocated to shareholders’ equity. (i) Revenue recognition The Company accounts for revenue in accordance with the provisions of ASC topic 605 Revenue Recognition. The Company earns revenue from non-refundable upfront fees, milestone payments upon achievement of specified research or development, exclusivity milestone payments and licensing payments on sales of resulting products. Revenue is realized or realizable and earned when evidence of an arrangement exists, delivery has occurred or services have been rendered, the price to the customer is fixed or determinable, and collectability is reasonably assured. From time to time, the Company enters into transactions that represent multiple-element arrangements. Management evaluates arrangements with multiple deliverables to determine whether the deliverables represent one or more units of accounting for the purpose of revenue recognition. A delivered item is considered a separate unit of accounting if the delivered item has stand-alone value to the customer, the fair value of any undelivered items can be reliably determined, and the delivery of undelivered items is probable and substantially in the Company's control. The relevant revenue recognition accounting policy is applied to each separate unit of accounting. Licensing The Company recognizes revenue from the licensing of the Company's drug delivery technologies, products and product candidates. Licensing revenue is recognized as earned in accordance with the contract terms when the amounts can be reasonably estimated and collectability is reasonably assured. The Company has a license and commercialization agreement with Par Pharmaceutical Inc. (“Par”). Under the exclusive territorial license rights granted to Par, the agreement requires that Par manufacture, promote, market, sell and distribute the product. Licensing revenue amounts receivable by the Company under this agreement are calculated and reported to the Company by Par, with such amounts generally based upon net product sales and net profit which include estimates for chargebacks, rebates, product returns, and other adjustments. Licensing revenue payments received by the Company from Par under this agreement are not subject to further deductions for chargebacks, rebates, product returns, and other pricing adjustments. Based on this arrangement and the guidance per ASC topic 605, the Company records licensing revenue as earned in the consolidated statements of operations and comprehensive loss. The Company also has a license and commercial supply agreement with Mallinckrodt LLC (“Mallinckrodt”) which provides Mallinckrodt an exclusive license to market, sell and distribute in the U.S. three drug product candidates for which the Company has ANDAs filed with the FDA. Under the terms of this agreement, the Company is responsible for the manufacture of approved products for subsequent sale by Mallinckrodt in the U.S. market, one of which (the Company’s generic Seroquel XR®) received final approval from the FDA in 2017. Following receipt of final FDA approval for its generic Seroquel XR®, the Company began shipment of manufactured product to Mallinckrodt. Licensing revenue in respect of manufactured product is reported as revenue in accordance with ASC topic 605. Once product is sold by Mallinckrodt, the Company receives downstream licensing revenue amounts calculated and reported by Mallinckrodt, with such amounts generally based upon net product sales and net profit which includes estimates for chargebacks, rebates, product returns, and other adjustments. Such downstream licensing revenue payments received by the Company under this agreement are not subject to further deductions for chargebacks, rebates, product returns, and other pricing adjustments. Based on this agreement and the guidance per ASC topic 605, the Company records licensing revenue as earned in the consolidated statements of operations and comprehensive loss. Milestones The milestone method recognizes revenue on substantive milestone payments in the period the milestone is achieved. Milestones are considered substantive if all of the following conditions are met: (i) the milestone is commensurate with either the vendor’s performance to achieve the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from the vendor’s performance to achieve the milestone; (ii) the milestone relates solely to past performance; and (iii) the milestone is reasonable relative to all of the deliverables and payment terms within the arrangement. Non-substantive milestone payments that might be paid to the Company based on the passage of time or as a result of a partner’s performance are allocated to the units of accounting within the arrangement; they are recognized as revenue in a manner similar to those units of accounting. Research and development Under arrangements where the license fees and research and development activities can be accounted for as a separate unit of accounting, non-refundable upfront license fees are deferred and recognized as revenue on a straight-line basis over the expected term of the Company's continued involvement in the research and development process. Deferred revenue Deferred revenue represents the funds received from clients, for which the revenues have not yet been earned, as the milestones have not been achieved, or in the case of upfront fees for drug development, where the work remains to be completed. During the year ended November 30, 2016, the Company received an up-front payment of $3,000,000 from Mallinckrodt pursuant to the Mallinckrodt license and commercial supply agreement, and initially recorded it as deferred revenue, as it did not meet the criteria for recognition. For the year ended November 30, 2018, the Company recognized $300,000 (2017 - $300,000) of revenue based on a straight-line basis over the expected term of the Mallinckrodt agreement of 10 years. In 2015, the Company received an up-front payment of $150,000 from Teva Pharmaceuticals USA, Inc. which the Company recognized as revenue during the year ended November 30, 2017. As of November 30, 2018, the Company has recorded a deferred revenue balance of $2,362,500 (November 30, 2017 - $2,662,500) relating to the underlying contracts, of which $300,000 (November 30, 2017 - $300,000) is considered a current portion of deferred revenue. (j) Research and development costs Research and development costs related to continued research and development programs are expensed as incurred in accordance with ASC topic 730. However, materials and equipment are capitalized and amortized over their useful lives if they have alternative future uses. (k) Inventory Inventories comprise raw materials, work in process, and finished goods, which are valued at the lower of cost or market, on a first-in, first-out basis. Cost for work in process and finished goods inventories includes materials, direct labor, and an allocation of manufacturing overhead. Market for raw materials is replacement cost, and for work in process and finished goods is net realizable value. The Company evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand. As of November 30, 2018, the Company had raw materials inventories of $144,659 (2017 - $115,667), work in process of $73,927 (2017 - $Nil) and finished goods inventory of $33,065 (2017 - $Nil) relating to the Company’s generic Seroquel XR® product. The recoverability of the cost of any pre-launch inventories with a limited shelf life is evaluated based on the specific facts and circumstances surrounding the timing of the anticipated product launch. (l) Income taxes The Company uses the liability method of accounting for income taxes. Under the liability The Company accounts for income taxes in accordance with ASC topic 740-10. This ASC topic The Company records any interest related to income taxes in interest expense and penalties in selling, general and administrative expense. (m) Share issue costs Share issue costs are recorded as a reduction of the proceeds from the issuance of capital stock. (n) Translation of foreign currencies Transactions denominated in currencies other than the Company and its wholly owned operating subsidiaries’ functional currencies, monetary assets and liabilities are translated at the period end rates. Revenue and expenses are translated at rates of exchange prevailing on the transaction dates. All of the exchange gains or losses resulting from these other transactions are recognized in the consolidated statements of operations and comprehensive loss. The functional and reporting currency of the Company and its subsidiaries is the U.S. dollar. (o) Stock-based compensation The Company has a stock-based compensation plan which authorizes the granting of various equity-based incentives including stock options and restricted share units (“RSU”s). The Company calculates stock-based compensation using the fair value method, under which the fair value of the options at the grant date is calculated using the Black-Scholes Option Pricing Model, and subsequently expensed over the vesting period of the option. The provisions of the Company's stock-based compensation plans do not require the Company to settle any options by transferring cash or other assets, and therefore the Company classifies the awards as equity. Stock-based compensation expense recognized during the year is based on the value of stock-based payment awards that are ultimately expected to vest. The Company estimates forfeitures at the time of grant and are revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The stock-based compensation expense is recorded in the consolidated statements of operations and comprehensive loss under research and development expense and under selling, general and administration expense. Note 11 provides supplemental disclosure of the Company's stock options. (p) Deferred Share Units Deferred Share Units (“DSU”s) are valued based on the trading price of the Company’s common shares on the Toronto Stock Exchange. The Company records the value of the DSU’s owing to non-management board members in the consolidated statement of shareholders’ equity (deficiency). (q) Loss per share Basic loss per share (“EPS”) is computed by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of options, warrants and convertible securities are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. The dilutive effect of stock options is determined using the treasury stock method. Stock options and warrants to purchase 22,540,535, 980,791 and 754,027 common shares of the Company during fiscal 2018, 2017, and 2016, respectively, were not included in the computation of diluted EPS because the Company has incurred a loss for the years ended November 30, 2018, 2017 and 2016 as the effect would be anti-dilutive. (r) Comprehensive loss The Company follows ASC topic 220. This statement establishes standards for reporting and display of comprehensive (loss) income and its components. Comprehensive loss is net loss plus certain items that are recorded directly to shareholders' equity (deficiency). Other than foreign exchange gains and losses arising from cumulative translation adjustments, the Company has no other comprehensive loss items. (s) Fair value measurement Under ASC topic 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., an exit price). ASC topic 820 establishes a hierarchy for inputs to valuation techniques used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that reflect assumptions market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. There are three levels to the hierarchy based on the reliability of inputs, as follows: ● Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. ● Level 2 - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets and liabilities in markets that are not active. ● Level 3 - Unobservable inputs for the asset or liability. The degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. (t) Recently adopted accounting pronouncements In August 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2016-15, Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments, which makes eight targeted changes to how cash receipts and cash payments are presented and classified in the Statement of Cash Flows. ASU 2016-15 became effective on May 1, 2018. The Company adopted ASU 2016-15 and the amendments did not have any material impact on the Company’s financial position, results of operations, cash flows or disclosures. (u) Future accounting pronouncements In May 2014, the FASB issued ASU No. 2014-09 ( “Topic 606”) In January 2016, the FASB issued ASU No. 2016-01, which makes limited amendments to the guidance in U.S. GAAP on the classification and measurement of financial instruments. The new standard significantly revises an entity’s accounting related to (1) the classification and measurement of investments in equity securities and (2) the presentation of certain fair value changes for financial liabilities measured at fair value. It also amends certain disclosure requirements associated with the fair value of financial instruments. ASU No. 2016-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those annual periods. The Company anticipates that the adoption of this standard will not have a material impact on the Company’s financial position, results of operations, and cash flows. In February 2016, the FASB issued new guidance, ASU No. 2016-02, Leases (Topic 842). The main difference between current U.S. GAAP and the new guidance is the recognition of lease liabilities based on the present value of remaining lease payments and corresponding lease assets for operating leases under current U.S. GAAP with limited exception. Additional qualitative and quantitative disclosures are also required by the new guidance. Topic 842 is effective for annual reporting periods (including interim reporting periods) beginning after December 15, 2018. Early adoption is permitted. The Company is in the process of evaluating the amendments to determine if they have a material impact on the Company’s financial position, results of operations, cash flows or disclosures. In August 2016, the FASB issued ASU 2017-01 that changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. The guidance requires an entity to evaluate if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets; if so, the set of transferred assets and activities is not a business. ASU 2017-01 also requires a business to include at least one substantive process and narrows the definition of outputs by more closely aligning it with how outputs are described in ASC 606.1. ASU 2017-01 is effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those years. Early adoption is permitted. The Company does not expect the adoption of the amendments to have a material impact on the Company’s financial position, results of operations, cash flows or disclosures. In May 2017, the FASB issued ASU 2017-09 in relation to Compensation —Stock Compensation (Topic 718), Modification Accounting. The amendments provide guidance on changes to the terms or conditions of a share-based payment award, which require an entity to apply modification accounting in Topic 718. The amendments are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period, for (1) public business entities for reporting periods for which financial statements have not yet been issued and (2) all other entities for reporting periods for which financial statements have not yet been made available for issuance. The amendments should be applied prospectively to an award modified on or after the adoption date. The Company does not expect the adoption of the amendments to have a material impact on the Company’s financial position, results of operations, cash flows or disclosures.

Note 4 - Accounts Receivable

Note 4 - Accounts Receivable	12 Months Ended
	Nov. 30, 2018
Receivables [Abstract]
Accounts Receivable	The Company currently has no debt agreements in place whereby any amount of receivables serve as collateral. The Company has no off-balance-sheet credit exposures and has no foreclosed or repossessed assets. Accounts receivable are carried on the consolidated balance sheet net of allowance for doubtful accounts. This provision is established based on the Company’s best estimates regarding the ultimate recovery of balances for which collection is uncertain. As at November 30, 2018, the Company has an account receivable balance of $305,912 (2017 - $756,468) and an allowance for doubtful accounts of $66,849 (2017 - $66,849). Risks and uncertainties and credit quality information related to accounts receivable have been disclosed in Note 17.

Note 5 - Property and Equipment

Note 5 - Property and Equipment	12 Months Ended
	Nov. 30, 2018
Property, Plant and Equipment [Abstract]
Property and Equipment	Computer equipment Computer software Furniture and fixtures Laboratory equipment Leasehold improvements Laboratory equipment under capital lease Computer equipment under capital lease Total Cost Balance at November 30, 2016 $ 295,296 $ 124,151 $ 129,860 $ 3,933,693 $ 1,205,811 $ 276,300 $ 76,458 $ 6,041,569 Additions 235,454 31,908 42,638 1,353,110 235,641 - - 1,898,751 Balance at November 30, 2017 530,750 156,059 172,498 5,286,803 1,441,452 276,300 76,458 7,940,320 Additions 20,336 - - 80,842 - - - 101,178 Balance at November 30, 2018 551,086 156,059 172,498 5,367,645 1,441,452 276,300 76,458 8,041,498 Accumulated depreciation Balance at November 30, 2016 238,672 117,506 109,243 2,290,074 1,143,792 179,422 73,222 4,151,931 Depreciation 47,811 13,622 10,747 379,158 49,154 19,376 970 520,838 Balance at November 30, 2017 286,483 131,128 119,990 2,669,232 1,192,946 198,798 74,192 4,672,769 Depreciation 77,179 12,465 10,501 413,576 82,835 15,500 680 612,736 Balance at November 30, 2018 363,662 143,593 130,491 3,082,808 1,275,781 214,298 74,872 5,285,505 Net book value at: November 30, 2017 $ 244,267 $ 24,931 $ 52,508 $ 2,617,571 $ 248,506 $ 77,502 $ 2,266 $ 3,267,551 Balance at November 30, 2018 $ 187,424 $ 12,466 $ 42,007 $ 2,284,837 $ 165,671 $ 62,002 $ 1,586 $ 2,755,993 As at November 30, 2018, there was $595,589 (November 30, 2017 - $728,309; November 30, 2016 - $266,963) of laboratory equipment that was not available for use and therefore, no depreciation has been recorded for such laboratory equipment. As at November 30, 2018, there was $Nil (November 30, 2017 - $75,005) unpaid balance for purchased equipment. During the year ended November 30, 2018, the Company recorded depreciation expense within cost of goods sold of $2,352 (November 30, 2017 - $13,877; November 30, 2016 - $Nil). Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment is assessed by comparing the carrying amount of an asset with the sum of the undiscounted cash flows expected from its use and disposal, and as such requires the Company to make significant estimates on expected revenues from the commercialization of its products and services and the related expenses. The Company records a write-down for long-lived assets which have been abandoned and do not have any residual value. For the year ended November 30, 2018, the Company recorded a $Nil write-down of long-lived assets (2017 - $Nil; 2016 – $Nil).

Note 6 - Accrued Liabilities

Note 6 - Accrued Liabilities	12 Months Ended
	Nov. 30, 2018
Payables and Accruals [Abstract]
Accrued Liabilities	November 30, 2018 November 30, 2017 $ $ Professional fees 229,170 400,796 Property taxes - 111,970 Interest 17,413 54,110 Other 106,564 215,493 353,147 782,369

Note 7 - Due to Related Parties

Note 7 - Due to Related Parties	12 Months Ended
	Nov. 30, 2018
Related Party Transactions [Abstract]
Due to Related Parties	Convertible debentures Amounts due to the related parties are payable to entities controlled by two shareholders who are also officers and directors of the Company. November 30, November 30, 2018 2017 Convertible debenture payable to two directors and officers of the Company, unsecured, 12% annual interest rate, Payable monthly (“2013 Debenture”) $1,350,000 $1,290,465 Convertible debenture payable to two directors and officers of the Company, unsecured, 10% annual interest rate, Payable monthly (“2018 Debenture”) $440,358 - $1,790,358 $1,290,465 On January 10, 2013, the Company completed a private placement financing of the unsecured convertible 2013 Debenture (as defined above) in the original principal amount of $1.5 million, which had an original maturity date of January 1, 2015. The 2013 Debenture bears interest at a rate of 12% per annum, payable monthly, is pre-payable at any time at the option of the Company and is convertible at any time into common shares at a conversion price of $30.00 per common share at the option of the holder. Dr. Isa Odidi and Dr. Amina Odidi, shareholders, directors and executive officers of the Company purchased the 2013 Debenture and provided the Company with the $1.5 million of the proceeds for the 2013 Debenture. Effective October 1, 2014, the maturity date of the 2013 Debenture was extended to July 1, 2015. Under ASC 470-50, the change in the debt instrument was accounted for as a modification of debt. The increase in the fair value of the conversion option at the date of the modification, in the amount of $126,414, was recorded as a reduction in the carrying value of the debt instrument with a corresponding increase to Additional paid-in-capital. The carrying amount of the debt instrument is accreted over the remaining life of the 2013 Debenture using a 15% effective rate of interest. Effective June 29, 2015, the July 1, 2015 maturity date for the 2013 Debenture was further extended to January 1, 2016. Under ASC 470-50, the change in the maturity date of the debt instrument resulted in an extinguishment of the original 2013 Debenture as the change in the fair value of the embedded conversion option was greater than 10% of the carrying amount of the 2013 Debenture. In accordance with ASC 470-50-40, the 2013 Debenture was recorded at fair value. The difference between the fair value of the convertible 2013 Debenture after the extension and the net carrying value of the 2013 Debenture prior to the extension of $114,023 was recognized as a loss on the statement of operations and comprehensive loss. The carrying amount of the debt instrument was accreted to the face amount of the 2013 Debenture over the remaining life of the 2013 Debenture using a 14.6% effective rate of interest. Effective December 8, 2015, the January 1, 2016 maturity date of the 2013 Debenture was extended to July 1, 2016. Under ASC 470-50, the change in the debt instrument was accounted for as a modification of debt. The increase in the fair value of the conversion option at the date of the modification, in the amount of $83,101, was recorded as a reduction in the carrying value of the debt instrument with a corresponding increase to Additional paid-in-capital. The carrying amount of the debt instrument is accreted over the remaining life of the 2013 Debenture using a 6.6% effective rate of interest. Effective May 26, 2016, the July 1, 2016 maturity date of the 2013 Debenture was extended to December 1, 2016. Under ASC 470-50, the change in the debt instrument was accounted for as a modification of debt. The increase in the fair value of the conversion option at the date of the modification, in the amount of $19,808, was recorded as a reduction in the carrying value of the debt instrument with a corresponding increase to Additional paid-in-capital. The carrying amount of the debt instrument was accreted over the remaining life of the 2013 Debenture using a 4.2% effective rate of interest. Effective December 1, 2016, the maturity date of the 2013 Debenture was extended to April 1, 2017 and a principal repayment of $150,000 was made at the time of the extension. Under ASC 470-50, the change in the debt instrument was accounted for as a modification of debt. The increase in the fair value of the conversion option at the date of the modification, in the amount of $106,962, was recorded as a reduction in the carrying value of the debt instrument with a corresponding increase to Additional paid-in-capital. The carrying amount of the debt instrument is accreted over the remaining life of the 2013 Debenture using a 26.3% effective rate of interest. Effective March 28, 2017, the maturity date of the 2013 Debenture was extended to October 1, 2017. Under ASC 470-50, the change in the debt instrument was accounted for as a modification of debt. The increase in the fair value of the conversion option at the date of the modification, in the amount of $113,607, was recorded as a reduction in the carrying value of the debt instrument with a corresponding increase to Additional paid-in-capital. The carrying amount of the debt instrument is accreted over the remaining life of the 2013 Debenture using a 15.2% effective rate of interest. Effective September 28, 2017, the maturity date of the 2013 Debenture was extended to October 1, 2018. Under ASC 470-50, the change in the debt instrument was accounted for as a modification of debt. The increase in the fair value of the conversion option at the date of the modification, in the amount of $53,227, was recorded as a reduction in the carrying value of the debt instrument with a corresponding increase to Additional paid-in-capital. The carrying amount of the debt instrument is accreted over the remaining life of the 2013 Debenture using a 4.9% effective rate of interest. Effective October 1, 2018, the maturity date for the 2013 Debenture was extended to April 1, 2019. Under ASC 470-50, the change in the debt instrument was accounted for as a modification of debt. There was no change in the fair value of the conversion option at the date of the modification. The carrying amount of the debt instrument is accreted over the remaining life of the 2013 Debenture using a nominal effective rate of interest. On September 10, 2018, the Company completed a private placement financing of the unsecured convertible 2018 Debenture (as defined above) in the principal amount of $0.5 million. The 2018 Debenture will mature on September 1, 2020. The 2018 Debenture bears interest at a rate of 10% per annum, payable monthly, is pre-payable at any time at the option of the Company and is convertible at any time into common shares of the Company at a conversion price of $3.00 per common share at the option of the holder. Dr. Isa Odidi and Dr. Amina Odidi, who are shareholders, directors and executive officers of the Company provided the Company with the $0.5 million of the proceeds for the 2018 Debenture. At issuance, as the conversion price was lower than the market share price, the beneficial conversion feature valued at September 10, 2018 of $66,667 was allocated to Additional paid-in capital. The fair value of the 2018 Debenture will subsequently be accreted over the remaining life of the 2018 Debenture using an effective rate of interest of 7.3%. Accreted interest expense during the year ended November 30, 2018 is $66,560 (2017 - $219,497; 2016 - $79,245), and has been included in the consolidated statements of operations and comprehensive loss. In addition, the coupon interest on the convertible debentures for the year ended November 30, 2018 is $172,977 (2017 - $162,530; 2016 - $180,370), and has also been included in the consolidated statements of operations and comprehensive loss.

Note 8 - Employee Costs Payable

Note 8 - Employee Costs Payable	12 Months Ended
	Nov. 30, 2018
Compensation Related Costs [Abstract]
Employee Costs Payable	As at November 30, 2018, the Company had $222,478 (2017 - $214,980) accrued vacation payable to certain employees. This balance is due on demand and therefore presented as current liabilities.

Note 9 - Lease Obligations

Note 9 - Lease Obligations	12 Months Ended
	Nov. 30, 2018
Leases, Capital [Abstract]
Lease Obligations	On December 1, 2015, the Company entered into a new lease agreement for the premises that it currently operates from, as well the adjoining property which is owned by the same landlord, for a 5 year term with a 5 year renewal option. The Company also has an option to purchase the combined properties after March 1, 2017 and up to November 30, 2020 based on a fair value purchase formula. Future minimum lease payments under leases with terms of one year or more are as follows at November 30, 2018: Operating Year ending November 30, Lease $ 2019 180,436 2020 180,436 360,872

Note 10 - Capital Stock

Note 10 - Capital Stock	12 Months Ended
	Nov. 30, 2018
Stockholders' Equity Note [Abstract]
Capital Stock	Authorized, issued and outstanding (a) The Company is authorized to issue an unlimited number of common shares, all without nominal or par value and an unlimited number of preference shares. As at November 30, 2018, the Company had 18,252,243 (November 30, 2017 – 3,470,451; November 30, 2016 – 2,978,999) common shares issued and outstanding and no preference shares issued and outstanding. As of November 30, 2018, there were 1,030,000 common shares to be issued due to exercise of 2018 Pre-Funded Warrants (as defined below), which were issued subsequently in December 2018. Two officers and directors of IPC owned directly and through their family holding company (“Odidi Holdco”) 578,131 (2017 – 578,131) common shares or approximately 3% (2017 – 17%) of IPC. Each common share of the Company entitles the holder thereof to one vote at any meeting of shareholders of the Company, except meetings at which only holders of a specified class of shares are entitled to vote. Holders of common shares of the Company are entitled to receive, as and when declared by the board of directors of the Company, dividends in such amounts as shall be determined by the board. The holders of common shares of the Company have the right to receive the remaining property of the Company in the event of liquidation, dissolution, or winding-up of the Company, whether voluntary or involuntary. The preference shares may at any time and from time to time be issued in one or more series. The board of directors will, by resolution, from time to time, before the issue thereof, fix the rights, privileges, restrictions and conditions attaching to the preference shares of each series. Except as required by law, the holders of any series of preference shares will not as such be entitled to receive notice of, attend or vote at any meeting of the shareholders of the Company. Holders of preference shares will be entitled to preference with respect to payment of dividends and the distribution of assets in the event of liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, or any other distribution of the assets of the Company among its shareholders for the purpose of winding up its affairs, on such shares over the common shares of the Company and over any other shares ranking junior to the preference shares. (b) In November 2013, the Company entered into an equity distribution agreement with Roth Capital Partners, LLC (“Roth”), pursuant to which the Company originally could from time to time sell up to 530,548 of the Company’s common shares for up to an aggregate of $16.8 million (or such lesser amount as may then be permitted under applicable exchange rules and securities laws and regulations) through at-the-market issuances on Nasdaq or otherwise. Under the equity distribution agreement, the Company was able at its discretion, from time to time, offer and sell common shares through Roth or directly to Roth for resale to the extent permitted under Rule 415 under the Securities Act of 1933, as amended, at such time and at such price as were acceptable to the Company, from time to time, by means of ordinary brokers’ transactions on Nasdaq or otherwise at market prices prevailing at the time of sale or as determined by the Company. The Company has paid Roth a commission, or allowed a discount, of 2.75% of the gross proceeds that the Company received from any sales of common shares under the equity distribution agreement. The Company also agreed to reimburse Roth for certain expenses relating to the at-the-market offering program. During the year ended November 30, 2018, an aggregate of Nil (2017 – 110,815; 2016 – 147,126) common shares were sold on Nasdaq for gross proceeds of $Nil (2017- $2,541,640; 2016 - $3,469,449), with net proceeds to the Company of $Nil (2017 - $2,468,474; 2016 - $3,368,674), respectively, under the at-the-market offering program. In March 2018, the Company terminated its continuous offering under the prospectus supplement dated July 18, 2017 and prospectus dated July 17, 2017 in respect of its at-the-market program. The underwriting agreement relating to the October 2018 offering described in Note 10 restricts the Company’s ability to use this equity distribution agreement. It contains a prohibition on the Company: (i) for a period of two years following the date of the underwriting agreement, from directly or indirectly in any at-the-market or continuous equity transaction, offer to sell, or otherwise dispose of shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for its shares of capital stock or (ii) for a period of five years following the closing, effecting or entering into an agreement to effect any issuance by the Company of common shares or common shares equivalents involving a certain variable rate transactions under an at-the-market offering agreement, whereby the Company may issue securities at a future determined price, except that, on or after the date that is two years after the closing, the Company may enter into an at-the-market offering agreement. (c) Direct costs related to the Company’s filing of a base shelf prospectus filed in May 2014 and declared effective in June 2014, direct costs related to the base shelf prospectus filed in May 2017 and certain other on-going costs related to the at the-market facility are recorded as deferred offering costs and are being amortized and recorded as share issuance costs against share offerings. For the year ended November 30, 2017, the Company recorded $137,363 as a financing cost in the statements of operations and comprehensive loss related to the base shelf prospectus filed in May 2014 and expired in July 2017 and to the at-the-market facility. For the year ended November 30, 2018, costs directly related to the at the-market facility of $Nil (2017 - $73,166; 2016 - $100,775) were recorded in share offering costs and $337,887 (2017 - $220,573; 2016 - $258,287) of deferred costs were amortized and recorded in share offering costs related to the at the-market facility and base shelf prospectus. For the year ended November 30, 2018, the Company recorded $174,802 as a financing cost in the statements of operations and comprehensive loss related to the at-the-market offering program filed in November 2013. (d) In June 2016, the Company completed an underwritten public offering of 322,981 units of common shares and warrants, at a price of $16.10 per unit, as further described in Note 14. The warrants are currently exercisable, have a term of five years and an exercise price of $19.30 per common share. The Company issued at the initial closing of the offering an aggregate of 322,981 common shares and warrants to purchase an additional 161,490 common shares. The underwriter also purchased at such closing additional warrants at a purchase price of $0.01 per warrant to acquire 24,223 common shares pursuant to the over-allotment option exercised in part by the underwriter. The Company subsequently sold an aggregate of 45,946 additional common shares at the public offering price of $16.10 per share in connection with subsequent partial exercises of the underwriter’s over-allotment option. The closings of these partial exercises brought the total net proceeds from the offering to $5,137,638, after deducting the underwriter’s discount and offering expenses. The warrants are considered to be indexed to the Company’s own stock and are therefore classified as equity under ASC topic 480 Distinguishing Liabilities from Equity. The Company recorded $4,764,777 as the value of common shares under Capital stock and $1,175,190 as the value of the warrants under Additional paid-in-capital in the consolidated statements of shareholders’ equity (deficiency). The Company has disclosed the terms used to value the warrants in Note 14. The direct costs related to the issuance of these units of common shares and warrants were $802,329 and were recorded as an offset against the statement of shareholders’ equity (deficiency) with $643,593 being recorded under Capital stock and $158,736 being recorded under Additional paid-in-capital. (e) In October 2017, the Company completed a registered direct offering of 363,636 common shares at a price of $11.00 per share. The Company also issued to the investors warrants to purchase an aggregate of 181,818 common shares (the “October 2017 Warrants”). The warrants became exercisable six months following the closing date, will expire 30 months after the date they became exercisable, have a term of three years and have an exercise price of $12.50 per common share. The Company also issued to the placement agents warrants to purchase 18,181 common shares at an exercise price of $13.75 per share (the “October 2017 Placement Agent Warrants”). The holders of October 2017 Warrants and October 2017 Placement Agent Warrants are entitled to a cashless exercise under which the number of shares to be issued will be based on the number of shares for which warrants are exercised times the difference between the market price of the common share and the exercise price divided by the market price. The October 2017 Warrants and the October 2017 Placement Agent Warrants are considered to be indexed to the Company’s own stock and are therefore classified as equity under ASC topic 480 Distinguishing Liabilities from Equity. The Company recorded $3,257,445 as the value of common shares under Capital stock and $742,555 as the value of the October 2017 Warrants under Additional paid-in-capital in the consolidated statements of shareholders’ equity (deficiency). The Company has disclosed the terms used to value the warrants in Note 14. The direct costs related to the issuance of the common shares, October 2017 Warrants and October 2017 Placement Agent Warrants were $500,492 and were recorded as an offset against the statement of shareholders’ equity (deficiency) with $391,580 being recorded under Capital stock and $108,912 being recorded under Additional paid-in-capital. (f) In March 2018, the Company completed two registered direct offerings of an aggregate of 883,333 common shares at a price of $6.00 per share. The Company also issued to the investors warrants to purchase an aggregate of 441,666 common shares (the “March 2018 Warrants”). The warrants became exercisable six months following the closing date, will expire 30 months after the date they became exercisable, and have an exercise price of $6.00 per common share. The Company also issued to the placement agents warrants to purchase 44,166 common shares at an exercise price of $7.50 per share (the “March 2018 Placement Agent Warrants”). The holders of March 2018 Warrants and March 2018 Placement Agent Warrants are entitled to a cashless exercise under which the number of shares to be issued will be based on the number of shares for which warrants are exercised times the difference between the market price of the common share and the exercise price divided by the market price. The March 2018 Warrants and March 2018 Placement Agent Warrants are considered to be indexed to the Company’s own stock and are therefore classified as equity under ASC topic 480 Distinguishing Liabilities from Equity. The Company recorded $4,184,520 as the value of common shares under Capital stock and $1,115,480 as the value of the March 2018 Warrants under Additional paid-in-capital in the consolidated statements of shareholders’ equity (deficiency). The Company has disclosed the terms used to value the warrants in Note 14. The direct costs related to the issuance of the common shares and warrants were $831,357 including the cost of warrants issued to the placement agents. These direct costs were recorded as an offset against the statement of shareholders’ equity (deficiency) with $656,383 being recorded under Capital stock and $174,974 being recorded under Additional paid-in-capital. (g) In October 2018, the Company completed an underwritten public offering in the United States, resulting in the sale to the public of 827,970 Units at $0.75 per Unit, which are comprised of one common share and one warrant (the “2018 Unit Warrants”) exercisable at $0.75 per share. The Company concurrently sold an additional 1,947,261 common shares and warrants to purchase 2,608,695 common shares exercisable at $0.75 per share (the “2018 Option Warrants’) pursuant to the over-allotment option exercised in part by the underwriter. The price of the common shares issued in connection with exercise of the over-allotment option was $0.74 per share and the price for the warrants issued in connection with the exercise of the over-allotment option was $0.01 per warrant, less in each case the underwriting discount. In addition, the Company issued 16,563,335 pre-funded units (“2018 Pre-Funded Units’), each 2018 Pre-Funded Unit comprising of one pre-funded warrant (a “2018 Pre-Funded Warrant”) to purchase one common share and one warrant (a “2018 Warrant”, and together with the 2018 Unit Warrants and the 2018 Option Warrants, the “2018 Firm Warrants”) to purchase one common share. The 2018 Pre-Funded Units were offered to the public at $0.74 each and a 2018 Pre-Funded Warrant is exercisable at $0.01 per share. Each 2018 Firm Warrant is exercisable immediately and has a term of five years and each 2018 Pre-Funded Warrant is exercisable immediately and until all 2018 Pre-Funded Warrants are exercised. The Company also issued warrants to the placement agents to purchase 1,160,314 common shares at an exercise price of $0.9375 per share (the “October 2018 Placement Agent Warrants”), which were exercisable immediately upon issuance. In aggregate, the Company issued 2,775,231 common shares, 16,563,335 2018 Pre-Funded Warrants and 20,000,000 2018 Firm Warrants in addition to 1,160,314 October 2018 Placement Agent Warrants. The Company raised $14,344,906 in gross proceeds as part of October 2018 underwritten public offering. The Company recorded $1,808,952 as the value of common shares under Capital stock and $279,086 as the value of the 2018 Firm Warrants and $12,256,868 as the value of the 2018 Pre-Funded Warrants under Additional paid-in-capital in the consolidated statements of shareholders’ equity (deficiency). During the year ended November 30, 2018, 12,153,334 2018 Pre-Funded Warrants were exercised for proceeds of $121,553, and the Company recorded a charge of $4,262,526 from Additional paid in capital to common shares under Capital stock. The Company has disclosed the terms used to value these warrants in Note 14. As of November 30, 2018, there were 1,030,000 common shares to be issued due to exercise of 2018 Pre-Funded Warrants; no other October 2018 Warrants had been exercised. The direct costs related to the issuance of the common shares and warrants issued in October 2018 were $2,738,710 including the cost of October 2018 Placement Agent Warrants in the amount of $461,697. These direct costs were recorded as an offset against the statement of shareholders’ equity (deficiency) with $345,363 being recorded under Capital stock and $2,393,347 being recorded under Additional paid-in-capital.

Note 11 - Options

Note 11 - Options	12 Months Ended
	Nov. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options	All grants of options to employees after October 22, 2009 are made from the Employee Stock Option Plan (the “Employee Stock Option Plan”). The maximum number of common shares issuable under the Employee Stock Option Plan is limited to 10% of the issued and outstanding common shares of the Company from time to time, or 1,825,224 based on the number of issued and outstanding common shares as at November 30, 2018. As at November 30, 2018, 279,257 options are outstanding and there were 1,545,967 options available for grant under the Employee Stock Option Plan. Each option granted allows the holder to purchase one common share at an exercise price not less than the closing price of the Company's common shares on the TSX on the last trading day prior to the grant of the option. Options granted under these plans typically have a term of 5 years with a maximum term of 10 years and generally vest over a period of up to three years. In August 2004, the Board of Directors of IPC Ltd. approved a grant of 276,394 performance-based stock options, to two executives who were also the principal shareholders of IPC Ltd. The vesting of these options is contingent upon the achievement of certain performance milestones. A total of 276,394 performance-based stock options have vested as of November 30, 2018. Under the terms of the original agreement these options were to expire in September 2014. Effective March 27, 2014, the Company’s shareholders approved the two year extension of the performance-based stock option expiry date to September 2016. Effective April 19, 2016, the Company’s shareholders approved a further two year extension of the performance-based stock option expiry date to September 2018. As a result of the modification of the performance-based stock option expiry date, the Company recorded additional compensation costs of $1,177,782 related to vested performance options during the year ended November 30, 2016. Effective May 15, 2018, the Company’s shareholders approved a further two year extension of the performance-based stock option expiry date to September 2020. As a result of the modification of the performance-based stock option expiry date, the Company recorded additional compensation costs of $45,793 related to vested performance options during the year ended November 30, 2018. These options were outstanding as at November 30, 2018. In the year ended November 30, 2018, Nil (2017 – 37,600; 2016 - 35,500) stock options were granted to management and other employees and Nil (2017 – 12,000; 2016 - 10,500) stock options were granted to members of the Board of Directors. The fair value of each option grant is estimated on the date of grant using the Black-Scholes Option-Pricing Model, consistent with the provisions of ASC topic 718. Option pricing models require the use of subjective assumptions, changes in these assumptions can materially affect the fair value of the options. The Company calculates expected volatility based on historical volatility of the Company’s peer group that is publicly traded for options that have an expected life that is more than nine years. For options that have an expected life of less than nine years the Company uses its own volatility. The expected term, which represents the period of time that options granted are expected to be outstanding, is estimated based on the historical average of the term and historical exercises of the options. The risk-free rate assumed in valuing the options is based on the U.S. treasury yield curve in effect at the time of grant for the expected term of the option. The expected dividend yield percentage at the date of grant is Nil as the Company is not expected to pay dividends in the foreseeable future. November 30, November 30, November 30, 2018 2017 2016 Volatility — 71.7 % 65.2 % Risk-free interest rate — 1.56 % 0.620 % Expected life (in years) — 5.49 5.00 Dividend yield — — — The weighted average grant date — $ 7.50 $ 12.00 Details of stock option transactions in Canadian dollars (“C$”) are as follows: November 30, 2018 November 30, 2017 November 30, 2016 Weighted Weighted Weighted average Weighted average Weighted average Weighted exercise average exercise average exercise average Number of price per grant date Number of price per grant date Number of price per grant date options share fair value options share fair value options share fair value $ $ $ $ $ $ Outstanding, beginning of year 582,811 32.00 17.20 539,246 34.80 18.80 506,200 38.90 22.10 Granted - - - 49,600 11.70 7.50 46,000 24.20 12.00 Exercised - - - (200) 23.20 12.00 (2,750) 25.70 16.80 Forfeiture (25,533) 20.36 14.19 - - - - - - Expired (1,627) 291.07 228.92 (5,835) 126.40 96.00 (10,204) 192.40 132.90 Balance, end of year 555,651 31.75 16.69 582,811 32.00 17.20 539,246 34.80 18.80 Options exercisable, end of year 544,619 32.16 16.91 522,106 33.00 17.90 439,661 34.90 19.60 As of November 30, 2018, the exercise prices, weighted average remaining contractual life of outstanding options and weighted average grant date fair values were as follows: Options outstanding Options exercisable Weighted Weighted Weighted Weighted Weighted average average average average average exercise remaining grant exercise grant Exercise Number price per contract date Number price per date price outstanding share life (years) fair value exercisable share fair value $ $ $ $ $ $ Under 25 109,067 17.99 2.66 9.75 98,035 14.14 10.15 26.00 - 50.00 446,584 35.11 1.98 29.25 446,584 35.11 29.25 555,651 31.75 544,619 32.16 Total unrecognized compensation cost relating to the unvested performance-based stock options at November 30, 2018 is approximately $Nil (2017 - $788,887; 2016 - $2,366,659). During the year ended November 30, 2018, specific performance conditions were met as the FDA approved one ANDA for certain drugs, resulting in the vesting of 27,640 performance-based stock options. As a result, a stock-based compensation expense of $793,795 relating to these stock options was recognized in research and development expense (2017 - $1,577,772; 2016 - $620,632). For the year ended November 30, 2018, no options were exercised. For the year ended November 30, 2017, 200 options were exercised for cash consideration of $1,742. For the year ended November 30, 2016, 2,750 options were exercised for a cash consideration of $52,868. The following table summarizes the components of stock-based compensation expense. November 30, November 30, November 30, 2018 2017 2016 $ $ $ Research and development 883,064 1,654,051 1,995,805 Selling, general and administrative 44,622 95,948 265,639 927,686 1,749,999 2,261,444

Note 12 - Deferred Share Units

Note 12 - Deferred Share Units	12 Months Ended
	Nov. 30, 2018
Deferred Compensation Arrangements Disclosure [Abstract]
Deferred Share Units	Effective May 28, 2010, the Company’s shareholders approved a Deferred Share Unit (“DSU”) Plan to grant DSUs to its non-management directors and reserved a maximum of 11,000 common shares for issuance under the plan. The DSU Plan permits certain non-management directors to defer receipt of all or a portion of their board fees until termination of the board service and to receive such fees in the form of common shares at that time. A DSU is a unit equivalent in value to one common share of the Company based on the trading price of the Company's common shares on the TSX. Upon termination of board service, the director will be able to redeem DSUs based upon the then market price of the Company's common shares on the date of redemption in exchange for any combination of cash or common shares as the Company may determine. During the years ended November 30, 2018 and 2017, one non-management board member elected to receive director fees in the form of DSUs under the Company’s DSU Plan. As at November 30, 2018, 10,279 (2017 – 9,413) DSUs are outstanding and 721 (2017 – 1,587) DSUs are available for grant under the DSU Plan. The Company recorded the following amounts related to DSUs for each of the three years ended November 30, 2018, 2017 and 2016 in Additional paid in capital and accrued the following amounts as at November 30, 2018, 2017 and 2016: November 30, 2018 November 30, 2017 November 30, 2016 $ shares $ shares $ shares Additional paid in capital 7,565 866 30,355 1,738 31,628 1,674 Accrued liability - - 7,562 866 7,261 235

Note 13 - Restricted Share Unit

Note 13 - Restricted Share Units	12 Months Ended
	Nov. 30, 2018
Disclosure Of Restricted Share Units [Abstract]
Restricted Share Units	Effective May 28, 2010, the Company’s shareholders approved a Restricted Share Unit (“RSU”) Plan for officers and employees of the Company and reserved a maximum of 33,000 common shares for issuance under the plan. The RSU Plan will form part of the incentive compensation arrangements available to officers and employees of the Company and its designated affiliates. An RSU is a unit equivalent in value to one common share of the Company. Upon vesting of the RSUs and the corresponding issuance of common shares to the participant, or on the forfeiture and cancellation of the RSUs, the RSUs credited to the participant’s account will be cancelled. No RSUs have been issued under the plan.

Note 14 - Warrants

Note 14 - Warrants	12 Months Ended
	Nov. 30, 2018
Warrants [Abstract]
Warrants	All of the Company’s outstanding warrants are considered to be indexed to the Company’s own stock and are therefore classified as equity under ASC 480. The warrants, in specified situations, provide for certain compensation remedies to a holder if the Company fails to timely deliver the shares underlying the warrants in accordance with the warrant terms. In the registered direct unit offering completed in March 2013, gross proceeds of $3,121,800 were received through the sale of the Company’s units comprised of common share and warrants. The offering was the sale of 181,500 units at a price of $17.20 per unit, with each unit consisting of one common share and a five year warrant to purchase 0.25 of a common share at an exercise price of $21.00 per share (the “March 2013 Warrants”). The fair value of the March 2013 Warrants of $407,558 were initially estimated at closing using the Black-Scholes Option Pricing Model, using volatilities of 63%, risk free interest rates of 0.40%, expected life of 5 years, and dividend yield of Nil. As at November 30, 2018, no March 2013 Warrants are outstanding. In the underwritten public offering completed in July 2013, gross proceeds of $3,075,000 were received through the sale of the Company’s units comprised of common shares and warrants. The offering was the sale of 150,000 units at a price of $20.50 per unit, each unit consisting of one common share and a five year warrant to purchase 0.25 of a common share at an exercise price of $25.50 per share (the “July 2013 Warrants”). As at November 30, 2018, no July 2013 Warrants are outstanding. The fair value of the July 2013 Warrants of $328,350 were initially estimated at closing using the Black-Scholes Option Pricing Model, using volatilities of 62.4%, risk free interest rates of 0.58%, expected life of 5 years, and dividend yield of Nil. In the underwritten public offering completed in June 2016, gross proceeds of $5,200,000 were received through the sale of the Company’s units comprised of common shares and warrants. The Company issued at the initial closing of the offering an aggregate of 322,981 common shares and warrants to purchase an additional 161,490 common shares, at a price of $16.10 per unit. The warrants are currently exercisable, have a term of five years and an exercise price of $19.30 per common share. The underwriter also purchased at such closing additional warrants (collectively with the warrants issued at the initial closing, the “June 2016 Warrants”) at a purchase price of $0.01 per warrant to acquire 24,223 common shares pursuant to the over-allotment option exercised in part by the underwriter. The fair value of the June 2016 Warrants of $1,175,190 was initially estimated at closing using the Black-Scholes Option Pricing Model, using volatility of 64.1%, risk free interest rates of 0.92%, expected life of 5 years, and dividend yield of Nil. The June 2016 Warrants currently outstanding are detailed below. In the registered direct offering completed in October 2017, gross proceeds of $4,000,000 were received through the sale of the Company’s common shares and warrants. The Company issued at the closing of the offering an aggregate of 363,636 common shares at a price of $11.00 per share and warrants to purchase an additional 181,818 common shares. The October 2017 Warrants became exercisable six months following the closing date, will expire 30 months after the date they became exercisable, and have an exercise price of $12.50 per common share. The Company also issued the October 2017 Placement Agents Warrants to purchase 18,181 common shares at an exercise price of $13.75 per share. The holders of October 2017 Warrants and October 2017 Placement Agent Warrants are entitled to a cashless exercise under which the number of shares to be issued will be based on the number of share for which warrants are exercised times the difference between the market price of the common share and the exercise price divided by the market price. The fair value of the October 2017 Warrants of $742,555 was initially estimated at closing using the Black- Scholes Option Pricing Model, using volatility of 73.67%, risk free interest rates of 1.64%, expected life of 3 years, and dividend yield of Nil. The fair value of the October 2017 Placement Agents Warrants was estimated at $86,196 using the Black-Scholes Option Pricing Model, using volatility of 73.67%, a risk free interest rate of 1.64%, an expected life of 3 years, and a dividend yield of Nil. The October 2017 Warrants and the October 2017 Placement Agent Warrants currently outstanding are detailed below. In the two registered direct offerings completed in March 2018, gross proceeds of $5,300,000 were received through the sale of the Company’s common shares and warrants. The Company issued at the closing of the offering an aggregate of 883,333 common shares at a price of $6.00 per share and the March 2018 Warrants to purchase an additional 441,666 common shares. The March 2018 Warrants became exercisable six months following the closing date, will expire 30 months after the date they became exercisable and have an exercise price of $6.00 per common share. The Company also issued the March 2018 Placement Agent Warrants to purchase 44,166 common shares at an exercise price of $7.50 per share. The holders of March 2018 Warrants and March 2018 Placement Agent Warrants are entitled to a cashless exercise under which the number of shares to be issued will be based on the number of share for which warrants are exercised times the difference between the market price of the common share and the exercise price divided by the market price. The fair value of the March 2018 Warrants of $1,115,480 was initially estimated at closing using the Black- Scholes Option Pricing Model, using volatility of 70%, risk free interest rates of 2.44% and 2.46%, expected life of 3 years, and dividend yield of Nil. The fair value of the March 2018 Placement Agent Warrants was estimated at $141,284 using the Black-Scholes Option Pricing Model, using volatility of 70%, risk free interest rates of 2.44% and 2.46%, an expected life of 3 years, and a dividend yield of Nil. The March 2018 Warrants and the March 2018 Placement Agent Warrants currently outstanding are detailed below. In October 2018, the Company completed an underwritten public offering in the United States, resulting in the sale to the public of 827,970 Units at $0.75 per Unit, which are comprised of one common share and one 2018 Unit Warrant (as defined above) exercisable at $0.75 per share. The Company concurrently sold an additional 1,947,261 common shares and 2,608,695 2018 Option Warrants exercisable at $0.75 per share pursuant to the over-allotment option exercised in part by the underwriter. The price of the common shares issued in connection with exercise of the over-allotment option was $0.74 per share and the price for the warrants issued in connection with the exercise of the over-allotment option was $0.01 per warrant, less in each case the underwriting discount. In addition, the Company issued 16,563,335 2018 Pre-Funded Units (as defined above), each 2018 Pre-Funded Unit consisting of one 2018 Pre-Funded Warrant (as defined above) to purchase one common share and one 2018 Warrant (as defined above) to purchase one common share. The 2018 Pre-Funded Units were offered to the public at $0.74 each and a 2018 Pre-Funded Warrant is exercisable at $0.01 per share. Each 2018 Firm Warrant is exercisable immediately and has a term of five years and each 2018 Pre-Funded Warrant is exercisable immediately and until all 2018 Pre-Funded Warrants are exercised. The Company also issued the October 2018 Placement Agent Warrants to the placement agents to purchase 1,160,314 common shares at an exercise price of $0.9375 per share, which were exercisable immediately upon issuance. In aggregate, in October 2018, the Company issued 2,775,231 common shares, 16,563,335 2018 Pre-Funded Warrants and 20,000,000 2018 Firm Warrants in addition to 1,160,314 October 2018 Placement Agent Warrants. The fair value of the 2018 Firm Warrants of $279,086 was initially estimated at closing using the Black-Scholes Option Pricing Model, using volatility of 92%, risk free interest rates of 3.02%, expected life of 5 years, and dividend yield of Nil. The fair value of the October 2018 Placement Agents Warrants was estimated at $461,697 using the Black-Scholes Option Pricing Model, using volatility of 92%, risk free interest rates of 3.02%, an expected life of 5 years, and a dividend yield of Nil. The fair value of the 2018 Pre-Funded Warrant of $12,256,868 and the fair value of the 2018 Firm Warrants of $279,086, respectively, were recorded under Additional paid-in-capital in the consolidated statements of shareholders’ equity (deficiency). During the year ended November 30, 2018, 12,153,334 2018 Pre-Funded Warrants were exercised for proceeds of $121,553, and the Company recorded a charge of $4,262,526 from Additional paid-in-capital to common shares under Capital stock. As at November 30, 2018, 4,410,001 2018 Pre-Funded Warrants are outstanding which are exercisable immediately at $0.01 per share. In addition, the following table provides information on the 22,123,623 warrants including 2018 Firm Warrants outstanding and exercisable as of November 30, 2018: Number Shares issuable Warrant Exercise price outstanding Expiry upon exercise June 2016 Warrants $ 19.30 277,478 June 2, 2021 138,739 October 2017 Warrants $ 12.50 181,818 October 13, 2020 181,818 October 2017 Placement Agent Warrants $ 13.750 18,181 October 13, 2020 18,181 March 2018 Warrants $ 6.00 291,666 March 16, 2021 291,666 March 2018 Warrants $ 6.00 150,000 March 21, 2021 150,000 March 2018 Placement Agent Warrants $ 7.50 29,166 March 16, 2021 29,166 March 2018 Placement Agent Warrants $ 7.50 15,000 March 21, 2021 15,000 2018 Firm Warrants $ 0.75 20,000,000 October 16, 2023 20,000,000 2018 Pre-Funded Warrants $ 0.01 4,410,001 October 16, 2023 4,410,001 October 2018 Placement Agent Warrants $ 0.9375 1,160,314 October 16, 2023 1,160,314 26,533,624 26,394,885 During the year ended November 30, 2018, other than Pre-Funded Warrants as noted above, there were no cash exercises in respect of warrants (2017 – 33,602; 2016 – 83,210) and no cashless exercise (2017 - Nil; 2016 - Nil) of warrants, resulting in the issuance of Nil (2017 – 16,801; 2016 – 35,791) and Nil (2017 - Nil; 2016 - Nil) common shares, respectively. For the warrants exercised, the Company recorded a charge to capital stock of $Nil (2017 - $430,573; 2016 - $1,030,719) comprised of proceeds of $Nil (2017 - $324,258; 2016 - $700,653) and the associated amount of $Nil (2017 - $106,315; 2016 - $330,066) previously recorded in Additional paid-in-capital. Details of warrant transactions for the years ended November 30, 2018 and 2017 are as follows: Outstanding, December 1, 2017 Issued Expired Exercised Rounding on consolidation Outstanding, November 30, 2018 March 2013 Warrants 149,174 - (149,174) - - - July 2013 Warrants 87,000 - (87,000) - - - June 2016 Warrants 277,872 - - - (394) 277,478 October 2017 Warrants 181,818 - - - - 181,818 October 2017 Placement Agent Warrants 18,181 - - - - 18,181 March 2018 Warrants - 441,666 - - - 441,666 March 2018 Placement Agent Warrants - 44,166 - - - 44,166 2018 Firm Warrants - 20,000,000 - - - 20,000,000 2018 Pre-Funded Warrants - 16,563,335 - (12,153,334) - 4,410,001 October 2018 Placement Agent Warrants - 1,160,314 - - - 1,160,314 714,045 38,209,481 (236,174) (12,153,334) (394) 26,533,624 March 2013 Warrants July 2013 Warrants June 2016 Warrants October 2017 Warrants October 2017 Placement Agent Warrants Total Outstanding, December 1, 2016 149,174 87,000 311,474 - - 547,648 Issued - - - 181,818 18,181 199,999 Exercised - - (33,602) - - (33,602) Outstanding, November 30, 2017 149,174 87,000 277,872 181,818 18,181 714,045

Note 15 - Income Taxes

Note 15 - Income Taxes	12 Months Ended
	Nov. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	The Company files Canadian income tax returns for its Canadian operations. Separate income tax returns are filed as locally required. The total provision for income taxes differs from the amount which would be computed by applying the Canadian income tax rate to loss before income taxes. The reasons for these differences are as follows: November 30, November 30, November 30, 2018 2017 2016 % % % Statutory income tax rate 26.5 26.5 26.5 $ $ $ Statutory income tax recovery (3,643,080) (2,347,222) (2,688,048) Increase (decrease) in income taxes Non-deductible expenses/ non-taxable income 263,650 488,769 640,481 Change in valuation allowance 4,861,770 2,128,819 2,683,775 Investment tax credit (466,052) - - Financing costs booked to equity (1,049,430) (269,715) (281,063) Difference in foreign tax rates 290 (651) - True up of tax returns 11,029 - (356,095) Tax loss expired and other 21,823 - 950 - - - The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities and certain carry-forward balances. Significant temporary differences and carry-forwards are as follows: November 30, November 30, November 30, 2018 2017 2016 $ $ $ Deferred tax assets Non-capital loss carry-forwards 11,847,710 8,972,285 7,427,516 Book and tax basis differences on assets and liabilities 1,041,360 863,215 3,409,343 Other 2,586,070 2,681,375 - Investment tax credit 3,354,760 2,865,404 2,405,365 Undeducted research and development expenditures 4,870,130 4,158,178 3,710,274 Capital loss carryforwards 326,060 326,064 - Share issuance cost 1,152,750 436,427 - Net operating loss carryforwards - 14,135 - 25,178,840 20,317,083 16,952,498 Valuation allowances for deferred tax assets (25,178,840) (20,317,083) (16,952,498) Net deferred tax assets - - - At November 30, 2018, the Company had cumulative operating losses available to reduce future years’ income for income tax purposes: Canadian income tax losses expiring in the year ended November 30, Federal $ 2028 182,222 2029 555,539 2030 3,373,079 2031 5,532,739 2032 5,750,053 2033 4,562,538 2034 149,927 2035 2,634,823 2036 5,341,606 2037 5,694,760 2038 10,931,052 44,708,338 At November 30, 2018, the Company had a cumulative carry-forward pool of Canadian Federal SR&ED expenditures in the amount of approximately $18,377,849 (2017 - $15,690,203) which can be carried forward indefinitely. At November 30, 2018, the Company had approximately $3,483,828 (2017 - $2,976,546) of unclaimed ITCs which expire from 2025 to 2038. These credits are subject to a full valuation allowance as they are not more likely than not to be realized. The net deferred tax assets have been fully offset by a valuation allowance because it is not more likely than not the Company will realize the benefit of these deferred tax assets. The Company does not have any recognized tax benefits as of November 30, 2018 or November 30, 2017. The Company files unconsolidated federal income tax returns domestically and in foreign jurisdictions. The Company has open tax years from 2009 to 2018 with tax jurisdictions including Canada and the U.S. These open years contain certain matters that could be subject to differing interpretations of applicable tax laws and regulations, as they relate to amount, timing, or inclusion of revenues and expenses. The Company did not incur any interest expense related to uncertain tax positions in 2018, 2017 and 2016 or any penalties in those years. The Company had no accrued interest and penalties as of November 30, 2018, 2017 and 2016. The Company had no unrecognized tax benefits in 2018, 2017 and 2016, and the Company does not expect that the unrecognized tax benefit will increase within the next twelve months.

Note 16 - Contingencies

Note 16 - Contingencies	12 Months Ended
	Nov. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Contingencies	From time to time, the Company may be exposed to claims and legal actions in the normal course of business. As at November 30, 2018, and continuing as at February 21, 2019, the Company is not aware of any pending or threatened material litigation claims against the Company, other than as described below. In November 2016, the Company filed an NDA for its abuse-deterrent oxycodone hydrochloride extended release tablets (formerly referred to as RexistaTM) (“Oxycodone ER”) product candidate, relying on the 505(b)(2) regulatory pathway, which allowed the Company to reference data from Purdue Pharma L.P.'s file for its OxyContin® extended release oxycodone hydrochloride. The Oxycodone ER application was accepted by the FDA for further review in February 2017. The Company certified to the FDA that it believed its Oxycodone ER product candidate would not infringe any of the OxyContin® patents listed in the Orange Book, or that such patents are invalid, and so notified Purdue Pharma L.P. and the other owners of the subject patents listed in the Orange Book of such certification. On April 7, 2017, the Company had received notice that Purdue Pharma L.P., Purdue Pharmaceuticals L.P., The P.F. Laboratories, Inc., or collectively the Purdue parties, Rhodes Technologies, and Grünenthal GmbH, or collectively the Purdue litigation plaintiffs, had commenced patent infringement proceedings against the Company in the U.S. District Court for the District of Delaware (docket number 17-392) in respect of the Company’s NDA filing for Oxycodone ER, alleging that its proposed Oxycodone ER infringes 6 out of the 16 patents associated with the branded product OxyContin®, or the OxyContin® patents, listed in the Orange Book. The complaint seeks injunctive relief as well as attorneys' fees and costs and such other and further relief as the Court may deem just and proper. An answer and counterclaim have been filed. Subsequent to the above-noted filing of lawsuit, 4 further such patents were listed and published in the Orange Book. The Company then similarly certified to the FDA concerning such further patents. On March 16, 2018, the Company received notice that the Purdue litigation plaintiffs had commenced further such patent infringement proceedings against the Company adding the 4 further patents. This lawsuit is also in the District of Delaware federal court under docket number 18-404. As a result of the commencement of the first of these legal proceedings, the FDA is stayed for 30 months from granting final approval to the Company’s Oxycodone ER product candidate. That time period commenced on February 24, 2017, when the Purdue litigation plaintiffs received notice of the Company’s certification concerning the patents, and will expire on August 24, 2019, unless the stay is earlier terminated by a final declaration of the courts that the patents are invalid, or are not infringed, or the matter is otherwise settled among the parties. On or about June 26, 2018 the court issued an order to sever 6 overlapping patents from the second Purdue case, but ordered litigation to proceed on the 4 new (2017-issued) patents. An answer and counterclaim was filed July 9, 2018. The existence and publication of additional patents in the Orange Book, and litigation arising therefrom, is an ordinary and to be expected occurrence in the course of such litigation. On July 6, 2018 the court issued a so-called “Markman” claim construction ruling on the first case and the October 22, 2018 trial date remained unchanged. The Company believes that it has non-infringement and/or invalidity defenses to all of the asserted claims of the subject patents in both of the cases and will vigorously defend against these claims. On July 24, 2018, the parties to the case mutually agreed to and did have dismissed without prejudice the infringement claims related to the Grünenthal ‘060 patent. The Grünenthal ‘060 patent is one of the six patents included in the original litigation case, however, the dismissal does not by itself result in a termination of the 30-month litigation stay. On October 4, 2018, the parties mutually agreed to postpone the scheduled court date pending a case status conference scheduled for December 17, 2018. At that time, further trial scheduling and other administrative matters were postponed pending the Company’s anticipated resubmission of the Oxycodone ER NDA to the FDA, which is due no later than February 28, 2019. In July 2017, three complaints were filed in the U.S. District Court for the Southern District of New York that were later consolidated under the caption Shanawaz v. Intellipharmaceutics Int’l Inc., et al., No. 1:17-cv-05761 (S.D.N.Y.). The lead plaintiffs filed a consolidated amended complaint on January 29, 2018. In the amended complaint, the lead plaintiffs assert claims on behalf of a putative class consisting of purchasers of our securities between May 21, 2015 and July 26, 2017. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by making allegedly false and misleading statements or failing to disclose certain information regarding our NDA for Oxycodone ER abuse-deterrent oxycodone hydrochloride extended release tablets. The complaint seeks, among other remedies, unspecified damages, attorneys’ fees and other costs, equitable and/or injunctive relief, and such other relief as the court may find just and proper. On March 30, 2018, the Company and the other defendants filed a motion to dismiss the amended complaint for failure to state a valid claim. The defendants’ motion to dismiss was granted in part, and denied in part, in an Order dated December 17, 2018. In its Order, the court dismissed certain of the plaintiffs’ securities claims, to the extent that the claims were based upon statements describing the Oxycodone ER product’s abuse-deterrent features and its bioequivalence to OxyContin. However, the court allowed the claims to proceed to the extent plaintiffs challenged certain public statements describing the contents of the Company’s Oxycodone ER NDA. Defendants filed an answer to the amended complaint on January 7, 2019, and discovery is ongoing. We intend to vigorously defend against the remainder of the claims asserted in the consolidated action. On February 21, 2019, the Company and its CEO, Dr. Isa Odidi, received a Statement of Claim concerning an action against them in the Superior Court of Justice of Ontario under the caption Victor Romita, plaintiff, and Intellipharmaceutics International Inc and Isa Odidi, defendants

Note 17 - Financial Instruments

Note 17 - Financial Instruments	12 Months Ended
	Nov. 30, 2018
Disclosure Text Block Supplement [Abstract]
Financial Instruments	(a) Fair values The Company follows ASC topic 820, “Fair Value Measurements” which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The provisions of ASC topic 820 apply to other accounting pronouncements that require or permit fair value measurements. ASC topic 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date; and establishes a three level hierarchy for fair value measurements based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. Inputs refers broadly to the assumptions that market participants would use in pricing the asset or liability, including assumptions about risk. To increase consistency and comparability in fair value measurements and related disclosures, the fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of the hierarchy are defined as follows: Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs for asset or liabilities. The categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. (i) The Company calculates expected volatility based on historical volatility of the Company’s peer group that is publicly traded for options that have an expected life that is more than eight years (Level 2) while the Company uses its own historical volatility for options that have an expected life of eight years or less (Level 1). (ii) The Company calculates the interest rate for the conversion option based on the Company’s estimated cost of raising capital (Level 2). An increase/decrease in the volatility and/or a decrease/increase in the discount rate would have resulted in an increase/decrease in the fair value of the conversion option and warrants. Fair value of financial assets and financial liabilities that are not measured at fair value on a recurring basis are as follows: November 30, 2018 November 30, 2017 Carrying Fair Carrying Fair amount value amount value $ $ $ $ Financial Liabilities Convertible debentures (i) 1,790,358 1,795,796 1,290,465 1,316,386 (i) The Company calculates the interest rate for the Debentures and due to related parties based on the Company’s estimated cost of raising capital and uses the discounted cash flow model to calculate the fair value of the Debentures and the amounts due to related parties. The carrying values of cash, accounts receivable, accounts payable, accrued liabilities and employee cost payable approximates their fair values because of the short-term nature of these instruments. (b) Interest rate and credit risk Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in interest rates. The Company does not believe that the results of operations or cash flows would be affected to any significant degree by a sudden change in market interest rates, relative to interest rates on cash and the convertible debenture due to the short-term nature of these obligations. Trade accounts receivable potentially subjects the Company to credit risk. The Company provides an allowance for doubtful accounts equal to the estimated losses expected to be incurred in the collection of accounts receivable. The following table sets forth details of the aged accounts receivable that are not overdue as well as an analysis of overdue amounts and the related allowance for doubtful accounts: November 30, November 30, 2018 2017 $ $ Total accounts receivable 305,912 756,468 Less allowance for doubtful accounts (66,849) (66,849) Total accounts receivable, net 239,063 689,619 Not past due 239,063 689,619 Past due for more than 31 days but no more than 120 days - 5,176 Past due for more than 120 days 66,849 61,673 Total accounts receivable, gross 305,912 756,468 Financial instruments that potentially subject the Company to concentration of credit risk consist principally of uncollateralized accounts receivable. The Company’s maximum exposure to credit risk is equal to the potential amount of financial assets. For the year ended November 30, 2018 and 2017, two customers accounted for substantially all the revenue and all the accounts receivable of the Company. The Company is also exposed to credit risk at period end from the carrying value of its cash. The Company manages this risk by maintaining bank accounts with a Canadian Chartered Bank. The Company’s cash is not subject to any external restrictions. (c) Foreign exchange risk The Company has balances in Canadian dollars that give rise to exposure to foreign exchange (“FX”) risk relating to the impact of translating certain non-U.S. dollar balance sheet accounts as these statements are presented in U.S. dollars. A strengthening U.S. dollar will lead to a FX loss while a weakening U.S. dollar will lead to a FX gain. For each Canadian dollar balance of $1.0 million, a +/- 10% movement in the Canadian currency held by the Company versus the U.S. dollar would affect the Company’s loss and other comprehensive loss by $0.1 million. (d) Liquidity risk Liquidity risk is the risk that the Company will encounter difficulty raising liquid funds to meet commitments as they fall due. In meeting its liquidity requirements, the Company closely monitors its forecasted cash requirements with expected cash drawdown. The following are the contractual maturities of the undiscounted cash flows of financial liabilities as at November 30, 2018: Less than 3 to 6 6 to 9 9 months Greater than 3 months months months to 1 year 1 year Total $ $ $ $ $ $ Third parties Accounts payable 2,643,437 - - - - 2,643,437 Accrued liabilities 353,147 - - - - 353,147 Related parties Employee costs payable 222,478 - - - - 222,478 Convertible debentures (Note 7) 52,274 1,376,805 12,603 12,466 537,808 1,991,956 3,271,336 1,376,805 12,603 12,466 537,808 5,211,018

Note 18 - Segmented Information

Note 18 - Segmented Information	12 Months Ended
	Nov. 30, 2018
Segment Reporting [Abstract]
Segmented Information	The Company's operations comprise a single reportable segment engaged in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. As the operations comprise a single reportable segment, amounts disclosed in the financial statements for revenue, loss for the period, depreciation and total assets also represent segmented amounts. In addition, all of the Company's long-lived assets are in Canada. The Company’s license and commercialization agreement with Par accounts for substantially all of the revenue of the Company. November 30, November 30, November 30, 2018 2017 2016 $ $ $ Revenue United States 1,712,731 5,504,452 2,247,002 1,712,731 5,504,452 2,247,002 Total assets Canada 11,474,227 7,396,781 7,974,689 Total property and equipment Canada 2,755,993 3,267,551 1,889,638

Note 19 - Subsequent Event

Note 19 - Subsequent Event	12 Months Ended
	Nov. 30, 2018
Note 19 - Subsequent Event
Subsequent Event	In December 2018, a principal repayment of $300,000 was made for the 2013 Debenture to Drs. Isa and Amina Odidi.

Note 3 - Significant Accounti_2

Note 3 - Significant Accounting Policies (Policies)	12 Months Ended
	Nov. 30, 2018
Accounting Policies [Abstract]
Cash and cash equivalents	The Company considers all highly liquid securities with an original maturity of three months or less to be cash equivalents. Cash equivalent balances consist of bankers’ acceptances and bank accounts with variable market rates of interest. The financial risks associated with these instruments are minimal and the Company has not experienced any losses from investments in these securities. The carrying amount of cash approximates its fair value due to its short-term nature. As at November 30, 2018 and 2017, the Company had no cash equivalents.
Accounts receivable	The Company reviews its sales and accounts receivable aging and determines whether an allowance for doubtful accounts is required.
Financial instruments	The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are classified as liabilities, the derivative instrument is initially recorded at its fair value using the appropriate valuation methodology and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations and comprehensive loss.
Investment tax credits	The investment tax credits (“ITC") receivable are amounts considered recoverable from the Canadian federal and provincial governments under the Scientific Research & Experimental Development (“SR&ED”) incentive program. The amounts claimed under the program represent the amounts based on management estimates of eligible research and development costs incurred during the year. Realization is subject to government approval. Any adjustment to the amounts claimed will be recognized in the year in which the adjustment occurs. Refundable ITCs claimed relating to capital expenditures are credited to property and equipment. Refundable ITCs claimed relating to current expenditures are netted against research and development expenditures.
Property and equipment	Property and equipment are recorded at cost. Equipment acquired under capital leases are recorded net of imputed interest, based upon the net present value of future payments. Assets under capital leases are pledged as collateral for the related lease obligation. Repairs and maintenance expenditures are charged to operations; major betterments and replacements are capitalized. Depreciation bases and rates are as follows: Assets Basis Rate Computer equipment Declining balance 30% Computer software Declining balance 50% Furniture and fixtures Declining balance 20% Laboratory equipment Declining balance 20% Leasehold improvements Straight line Over term of lease Leasehold improvements and assets acquired under capital leases are depreciated over the term of their useful lives or the lease period, whichever is shorter. The charge to operations resulting from depreciation of assets acquired under capital leases is included with depreciation expense.
Impairment of long-lived assets	Long-lived assets are reviewed for impairment when events or circumstances indicate that the carrying value of an asset may not be recoverable. For assets that are to be held and used, impairment is recognized when the sum of estimated undiscounted cash flows associated with the asset or group of assets is less than its carrying value. If impairment exists, an adjustment is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value.
Warrants	The Company previously issued warrants as described in Notes 10 and 14. In fiscal 2013, the outstanding warrants were presented as a liability because they did not meet the criteria of Accounting Standard Codification (“ASC”) topic 480 Distinguishing Liabilities from Equity for equity classification. Subsequent changes in the fair value of the warrants were recorded in the consolidated statements of operations and comprehensive loss. The Company changed its functional currency effective December 1, 2013 such that these warrants met the criteria for prospective equity classification in ASC topic 480, and the U.S. dollar translated amount of the warrant liability at December 1, 2013 became the amount reclassified to equity.
Convertible debentures	In fiscal 2013, the Company issued an unsecured convertible debenture in the principal amount of $1.5 million (the “2013 Debenture”) as described in Note 7. At issuance, the conversion option was bifurcated from its host contract and the fair value of the conversion option was characterized as an embedded derivative upon issuance as it met the criteria of ASC topic 815 Derivatives and Hedging. Subsequent changes in the fair value of the embedded derivative were recorded in the consolidated statements of operations and comprehensive loss. The proceeds received from the 2013 Debenture less the initial amount allocated to the embedded derivative were allocated to the liability and were accreted over the life of the 2013 Debenture using the effective rate of interest. The Company changed its functional currency effective December 1, 2013 such that the conversion option no longer met the criteria for bifurcation and was prospectively reclassified to shareholders’ equity under ASC Topic 815 at the U.S. dollar translated amount at December 1, 2013. On September 10, 2018, the Company completed a private placement financing of an unsecured convertible debenture in the principal amount of $0.5 million (the “2018 Debenture”) as described in Note 7. At issuance, the conversion price was lower than the market share price, and the value of the beneficial conversion feature related to the 2018 Debenture was allocated to shareholders’ equity.
Revenue recognition	The Company accounts for revenue in accordance with the provisions of ASC topic 605 Revenue Recognition. The Company earns revenue from non-refundable upfront fees, milestone payments upon achievement of specified research or development, exclusivity milestone payments and licensing payments on sales of resulting products. Revenue is realized or realizable and earned when evidence of an arrangement exists, delivery has occurred or services have been rendered, the price to the customer is fixed or determinable, and collectability is reasonably assured. From time to time, the Company enters into transactions that represent multiple-element arrangements. Management evaluates arrangements with multiple deliverables to determine whether the deliverables represent one or more units of accounting for the purpose of revenue recognition. A delivered item is considered a separate unit of accounting if the delivered item has stand-alone value to the customer, the fair value of any undelivered items can be reliably determined, and the delivery of undelivered items is probable and substantially in the Company's control. The relevant revenue recognition accounting policy is applied to each separate unit of accounting. Licensing The Company recognizes revenue from the licensing of the Company's drug delivery technologies, products and product candidates. Licensing revenue is recognized as earned in accordance with the contract terms when the amounts can be reasonably estimated and collectability is reasonably assured. The Company has a license and commercialization agreement with Par Pharmaceutical Inc. (“Par”). Under the exclusive territorial license rights granted to Par, the agreement requires that Par manufacture, promote, market, sell and distribute the product. Licensing revenue amounts receivable by the Company under this agreement are calculated and reported to the Company by Par, with such amounts generally based upon net product sales and net profit which include estimates for chargebacks, rebates, product returns, and other adjustments. Licensing revenue payments received by the Company from Par under this agreement are not subject to further deductions for chargebacks, rebates, product returns, and other pricing adjustments. Based on this arrangement and the guidance per ASC topic 605, the Company records licensing revenue as earned in the consolidated statements of operations and comprehensive loss. The Company also has a license and commercial supply agreement with Mallinckrodt LLC (“Mallinckrodt”) which provides Mallinckrodt an exclusive license to market, sell and distribute in the U.S. three drug product candidates for which the Company has ANDAs filed with the FDA, one of which (the Company’s generic Seroquel XR®) received final approval from the FDA in 2017. Under the terms of this agreement, the Company is responsible for the manufacture of approved products for subsequent sale by Mallinckrodt in the U.S. market. Following receipt of final FDA approval for its generic Seroquel XR®, the Company began shipment of manufactured product to Mallinckrodt. Licensing revenue in respect of manufactured product is reported as revenue in accordance with ASC topic 605. Once product is sold by Mallinckrodt, the Company receives downstream licensing revenue amounts calculated and reported by Mallinckrodt, with such amounts generally based upon net product sales and net profit which includes estimates for chargebacks, rebates, product returns, and other adjustments. Such downstream licensing revenue payments received by the Company under this agreement are not subject to further deductions for chargebacks, rebates, product returns, and other pricing adjustments. Based on this agreement and the guidance per ASC topic 605, the Company records licensing revenue as earned in the consolidated statements of operations and comprehensive loss. Milestones The milestone method recognizes revenue on substantive milestone payments in the period the milestone is achieved. Milestones are considered substantive if all of the following conditions are met: (i) the milestone is commensurate with either the vendor’s performance to achieve the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from the vendor’s performance to achieve the milestone; (ii) the milestone relates solely to past performance; and (iii) the milestone is reasonable relative to all of the deliverables and payment terms within the arrangement. Non-substantive milestone payments that might be paid to the Company based on the passage of time or as a result of a partner’s performance are allocated to the units of accounting within the arrangement; they are recognized as revenue in a manner similar to those units of accounting. Research and development Under arrangements where the license fees and research and development activities can be accounted for as a separate unit of accounting, non-refundable upfront license fees are deferred and recognized as revenue on a straight-line basis over the expected term of the Company's continued involvement in the research and development process. Deferred revenue Deferred revenue represents the funds received from clients, for which the revenues have not yet been earned, as the milestones have not been achieved, or in the case of upfront fees for drug development, where the work remains to be completed. During the year ended November 30, 2016, the Company received an up-front payment of $3,000,000 from Mallinckrodt pursuant to the Mallinckrodt license and commercial supply agreement, and initially recorded it as deferred revenue, as it did not meet the criteria for recognition. For the year ended November 30, 2018, the Company recognized $300,000 (2017 - $300,000) of revenue based on a straight-line basis over the expected term of the Mallinckrodt agreement of 10 years. In 2015, the Company received an up-front payment of $150,000 from Teva Pharmaceuticals USA, Inc. which the Company recognized as revenue during the year ended November 30, 2017. As of November 30, 2018, the Company has recorded a deferred revenue balance of $2,362,500 (November 30, 2017 - $2,662,500) relating to the underlying contracts, of which $300,000 (November 30, 2017 - $300,000) is considered a current portion of deferred revenue.
Research and development expense	Research and development costs related to continued research and development programs are expensed as incurred in accordance with ASC topic 730. However, materials and equipment are capitalized and amortized over their useful lives if they have alternative future uses.
Inventory	Inventories comprise raw materials, work in process, and finished goods, which are valued at the lower of cost or market, on a first-in, first-out basis. Cost for work in process and finished goods inventories includes materials, direct labor, and an allocation of manufacturing overhead. Market for raw materials is replacement cost, and for work in process and finished goods is net realizable value. The Company evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand. As of November 30, 2018, the Company had raw materials inventories of $144,659 (2017 - $115,667), work in process of $73,927 (2017 - $Nil) and finished goods inventory of $33,065 (2017 - $Nil) relating to the Company’s generic Seroquel XR® product. The recoverability of the cost of any pre-launch inventories with a limited shelf life is evaluated based on the specific facts and circumstances surrounding the timing of the anticipated product launch.
Income taxes	The Company uses the liability method of accounting for income taxes. Under the liability The Company accounts for income taxes in accordance with ASC topic 740-10. This ASC topic The Company records any interest related to income taxes in interest expense and penalties in selling, general and administrative expense.
Share issue costs	Share issue costs are recorded as a reduction of the proceeds from the issuance of capital stock.
Translation of foreign currencies	Transactions denominated in currencies other than the Company and its wholly owned operating subsidiaries’ functional currencies, monetary assets and liabilities are translated at the period end rates. Revenue and expenses are translated at rates of exchange prevailing on the transaction dates. All of the exchange gains or losses resulting from these other transactions are recognized in the consolidated statements of operations and comprehensive loss. The functional and reporting currency of the Company and its subsidiaries is the U.S. dollar.
Stock-based compensation	The Company has a stock-based compensation plan which authorizes the granting of various equity-based incentives including stock options and restricted share units (“RSU”s). The Company calculates stock-based compensation using the fair value method, under which the fair value of the options at the grant date is calculated using the Black-Scholes Option Pricing Model, and subsequently expensed over the vesting period of the option. The provisions of the Company's stock-based compensation plans do not require the Company to settle any options by transferring cash or other assets, and therefore the Company classifies the awards as equity. Stock-based compensation expense recognized during the year is based on the value of stock-based payment awards that are ultimately expected to vest. The Company estimates forfeitures at the time of grant and are revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The stock-based compensation expense is recorded in the consolidated statements of operations and comprehensive loss under research and development expense and under selling, general and administration expense. Note 11 provides supplemental disclosure of the Company's stock options.
Deferred Share Units	Deferred Share Units (“DSU”s) are valued based on the trading price of the Company’s common shares on the Toronto Stock Exchange. The Company records the value of the DSU’s owing to non-management board members in the consolidated statement of shareholders’ equity (deficiency).
Loss per share	Basic loss per share (“EPS”) is computed by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of options, warrants and convertible securities are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. The dilutive effect of stock options is determined using the treasury stock method. Stock options and warrants to purchase 22,540,535, 980,791 and 754,027 common shares of the Company during fiscal 2018, 2017, and 2016, respectively, were not included in the computation of diluted EPS because the Company has incurred a loss for the years ended November 30, 2018, 2017 and 2016 as the effect would be anti-dilutive.
Comprehensive loss	The Company follows ASC topic 220. This statement establishes standards for reporting and display of comprehensive (loss) income and its components. Comprehensive loss is net loss plus certain items that are recorded directly to shareholders' equity (deficiency). Other than foreign exchange gains and losses arising from cumulative translation adjustments, the Company has no other comprehensive loss items.
Fair value measurement	Under ASC topic 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., an exit price). ASC topic 820 establishes a hierarchy for inputs to valuation techniques used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that reflect assumptions market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. There are three levels to the hierarchy based on the reliability of inputs, as follows: ● Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. ● Level 2 - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets and liabilities in markets that are not active. ● Level 3 - Unobservable inputs for the asset or liability. The degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.
Recently adopted accounting pronouncements	In August 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2016-15, Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments, which makes eight targeted changes to how cash receipts and cash payments are presented and classified in the Statement of Cash Flows. ASU 2016-15 became effective on May 1, 2018. The Company adopted ASU 2016-15 and the amendments did not have any material impact on the Company’s financial position, results of operations, cash flows or disclosures.
Future accounting pronouncements	In May 2014, the FASB issued ASU No. 2014-09 ( “Topic 606”) In January 2016, the FASB issued ASU No. 2016-01, which makes limited amendments to the guidance in U.S. GAAP on the classification and measurement of financial instruments. The new standard significantly revises an entity’s accounting related to (1) the classification and measurement of investments in equity securities and (2) the presentation of certain fair value changes for financial liabilities measured at fair value. It also amends certain disclosure requirements associated with the fair value of financial instruments. ASU No. 2016-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those annual periods. The Company anticipates that the adoption of this standard will not have a material impact on the Company’s financial position, results of operations, and cash flows. In February 2016, the FASB issued new guidance, ASU No. 2016-02, Leases (Topic 842). The main difference between current U.S. GAAP and the new guidance is the recognition of lease liabilities based on the present value of remaining lease payments and corresponding lease assets for operating leases under current U.S. GAAP with limited exception. Additional qualitative and quantitative disclosures are also required by the new guidance. Topic 842 is effective for annual reporting periods (including interim reporting periods) beginning after December 15, 2018. Early adoption is permitted. The Company is in the process of evaluating the amendments to determine if they have a material impact on the Company’s financial position, results of operations, cash flows or disclosures. In August 2016, the FASB issued ASU 2017-01 that changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. The guidance requires an entity to evaluate if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets; if so, the set of transferred assets and activities is not a business. ASU 2017-01 also requires a business to include at least one substantive process and narrows the definition of outputs by more closely aligning it with how outputs are described in ASC 606.1. ASU 2017-01 is effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those years. Early adoption is permitted. The Company does not expect the adoption of the amendments to have a material impact on the Company’s financial position, results of operations, cash flows or disclosures. In May 2017, the FASB issued ASU 2017-09 in relation to Compensation —Stock Compensation (Topic 718), Modification Accounting. The amendments provide guidance on changes to the terms or conditions of a share-based payment award, which require an entity to apply modification accounting in Topic 718. The amendments are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period, for (1) public business entities for reporting periods for which financial statements have not yet been issued and (2) all other entities for reporting periods for which financial statements have not yet been made available for issuance. The amendments should be applied prospectively to an award modified on or after the adoption date. The Company does not expect the adoption of the amendments to have a material impact on the Company’s financial position, results of operations, cash flows or disclosures.

Note 3 - Significant Accounti_3

Note 3 - Significant Accounting Policies (Tables)	12 Months Ended
	Nov. 30, 2018
Accounting Policies [Abstract]
Schedule of Depreciation Rates	Assets Basis Rate Computer equipment Declining balance 30% Computer software Declining balance 50% Furniture and fixtures Declining balance 20% Laboratory equipment Declining balance 20% Leasehold improvements Straight line Over term of lease

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment (Tables)	12 Months Ended
	Nov. 30, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Computer equipment Computer software Furniture and fixtures Laboratory equipment Leasehold improvements Laboratory equipment under capital lease Computer equipment under capital lease Total Cost Balance at November 30, 2016 $ 295,296 $ 124,151 $ 129,860 $ 3,933,693 $ 1,205,811 $ 276,300 $ 76,458 $ 6,041,569 Additions 235,454 31,908 42,638 1,353,110 235,641 - - 1,898,751 Balance at November 30, 2017 530,750 156,059 172,498 5,286,803 1,441,452 276,300 76,458 7,940,320 Additions 20,336 - - 80,842 - - - 101,178 Balance at November 30, 2018 551,086 156,059 172,498 5,367,645 1,441,452 276,300 76,458 8,041,498 Accumulated depreciation Balance at November 30, 2016 238,672 117,506 109,243 2,290,074 1,143,792 179,422 73,222 4,151,931 Depreciation 47,811 13,622 10,747 379,158 49,154 19,376 970 520,838 Balance at November 30, 2017 286,483 131,128 119,990 2,669,232 1,192,946 198,798 74,192 4,672,769 Depreciation 77,179 12,465 10,501 413,576 82,835 15,500 680 612,736 Balance at November 30, 2018 363,662 143,593 130,491 3,082,808 1,275,781 214,298 74,872 5,285,505 Net book value at: November 30, 2017 $ 244,267 $ 24,931 $ 52,508 $ 2,617,571 $ 248,506 $ 77,502 $ 2,266 $ 3,267,551 Balance at November 30, 2018 $ 187,424 $ 12,466 $ 42,007 $ 2,284,837 $ 165,671 $ 62,002 $ 1,586 $ 2,755,993

Note 6 - Accrued Liabilities (T

Note 6 - Accrued Liabilities (Tables)	12 Months Ended
	Nov. 30, 2018
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	November 30, 2018 November 30, 2017 $ $ Professional fees 229,170 400,796 Property taxes - 111,970 Interest 17,413 54,110 Other 106,564 215,493 353,147 782,369

Note 7 - Due to Related Parti_2

Note 7 - Due to Related Parties (Tables)	12 Months Ended
	Nov. 30, 2018
Related Party Transactions [Abstract]
Schedule of Related Party Transactions	November 30, November 30, 2018 2017 Convertible debenture payable to two directors and officers of the Company, unsecured, 12% annual interest rate, Payable monthly (“2013 Debenture”) $1,350,000 $1,290,465 Convertible debenture payable to two directors and officers of the Company, unsecured, 10% annual interest rate, Payable monthly (“2018 Debenture”) $440,358 - $1,790,358 $1,290,465

Note 9 - Lease Obligations (Tab

Note 9 - Lease Obligations (Tables)	12 Months Ended
	Nov. 30, 2018
Leases, Capital [Abstract]
Schedule of Future Minimum Lease Payments	Operating Year ending November 30, Lease $ 2019 180,436 2020 180,436 360,872

Note 11 - Options (Tables)

Note 11 - Options (Tables)	12 Months Ended
	Nov. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	November 30, November 30, November 30, 2018 2017 2016 Volatility — 71.7 % 65.2 % Risk-free interest rate — 1.56 % 0.620 % Expected life (in years) — 5.49 5.00 Dividend yield — — — The weighted average grant date — $ 7.50 $ 12.00
Schedule of Share-based Compensation, Stock Options, Activity	November 30, 2018 November 30, 2017 November 30, 2016 Weighted Weighted Weighted average Weighted average Weighted average Weighted exercise average exercise average exercise average Number of price per grant date Number of price per grant date Number of price per grant date options share fair value options share fair value options share fair value $ $ $ $ $ $ Outstanding, beginning of year 582,811 32.00 17.20 539,246 34.80 18.80 506,200 38.90 22.10 Granted - - - 49,600 11.70 7.50 46,000 24.20 12.00 Exercised - - - (200) 23.20 12.00 (2,750) 25.70 16.80 Forfeiture (25,533) 20.36 14.19 - - - - - - Expired (1,627) 291.07 228.92 (5,835) 126.40 96.00 (10,204) 192.40 132.90 Balance, end of year 555,651 31.75 16.69 582,811 32.00 17.20 539,246 34.80 18.80 Options exercisable, end of year 544,619 32.16 16.91 522,106 33.00 17.90 439,661 34.90 19.60
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range	Options outstanding Options exercisable Weighted Weighted Weighted Weighted Weighted average average average average average exercise remaining grant exercise grant Exercise Number price per contract date Number price per date price outstanding share life (years) fair value exercisable share fair value $ $ $ $ $ $ Under 25 109,067 17.99 2.66 9.75 98,035 14.14 10.15 26.00 - 50.00 446,584 35.11 1.98 29.25 446,584 35.11 29.25 555,651 31.75 544,619 32.16
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	November 30, November 30, November 30, 2018 2017 2016 $ $ $ Research and development 883,064 1,654,051 1,995,805 Selling, general and administrative 44,622 95,948 265,639 927,686 1,749,999 2,261,444

Note 12 - Deferred Share Units

Note 12 - Deferred Share Units (Tables)	12 Months Ended
	Nov. 30, 2018
Deferred Compensation Arrangements Disclosure [Abstract]
Schedule of Share-based Compensation, Restricted Stock Units Award Activity	November 30, 2018 November 30, 2017 November 30, 2016 $ shares $ shares $ shares Additional paid in capital 7,565 866 30,355 1,738 31,628 1,674 Accrued liability - - 7,562 866 7,261 235

Note 14 - Warrants (Tables)

Note 14 - Warrants (Tables)	12 Months Ended
	Nov. 30, 2018
Warrants [Abstract]
Schedule of Stockholders' Equity Note, Warrants or Rights	Number Shares issuable Warrant Exercise price outstanding Expiry upon exercise June 2016 Warrants $ 19.30 277,478 June 2, 2021 138,739 October 2017 Warrants $ 12.50 181,818 October 13, 2020 181,818 October 2017 Placement Agent Warrants $ 13.750 18,181 October 13, 2020 18,181 March 2018 Warrants $ 6.00 291,666 March 16, 2021 291,666 March 2018 Warrants $ 6.00 150,000 March 21, 2021 150,000 March 2018 Placement Agent Warrants $ 7.50 29,166 March 16, 2021 29,166 March 2018 Placement Agent Warrants $ 7.50 15,000 March 21, 2021 15,000 2018 Firm Warrants $ 0.75 20,000,000 October 16, 2023 20,000,000 2018 Pre-Funded Warrants $ 0.01 4,410,001 October 16, 2023 4,410,001 October 2018 Placement Agent Warrants $ 0.9375 1,160,314 October 16, 2023 1,160,314 26,533,624 26,394,885
Schedule Of Warrant Transactions	Outstanding, December 1, 2017 Issued Expired Exercised Rounding on consolidation Outstanding, November 30, 2018 March 2013 Warrants 149,174 - (149,174) - - - July 2013 Warrants 87,000 - (87,000) - - - June 2016 Warrants 277,872 - - - (394) 277,478 October 2017 Warrants 181,818 - - - - 181,818 October 2017 Placement Agent Warrants 18,181 - - - - 18,181 March 2018 Warrants - 441,666 - - - 441,666 March 2018 Placement Agent Warrants - 44,166 - - - 44,166 2018 Firm Warrants - 20,000,000 - - - 20,000,000 2018 Pre-Funded Warrants - 16,563,335 - (12,153,334) - 4,410,001 October 2018 Placement Agent Warrants - 1,160,314 - - - 1,160,314 714,045 38,209,481 (236,174) (12,153,334) (394) 26,533,624 March 2013 Warrants July 2013 Warrants June 2016 Warrants October 2017 Warrants October 2017 Placement Agent Warrants Total Outstanding, December 1, 2016 149,174 87,000 311,474 - - 547,648 Issued - - - 181,818 18,181 199,999 Exercised - - (33,602) - - (33,602) Outstanding, November 30, 2017 149,174 87,000 277,872 181,818 18,181 714,045

Note 15 - Income Taxes (Tables)

Note 15 - Income Taxes (Tables)	12 Months Ended
	Nov. 30, 2018
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	November 30, November 30, November 30, 2018 2017 2016 % % % Statutory income tax rate 26.5 26.5 26.5 $ $ $ Statutory income tax recovery (3,643,080) (2,347,222) (2,688,048) Increase (decrease) in income taxes Non-deductible expenses/ non-taxable income 263,650 488,769 640,481 Change in valuation allowance 4,861,770 2,128,819 2,683,775 Investment tax credit (466,052) - - Financing costs booked to equity (1,049,430) (269,715) (281,063) Difference in foreign tax rates 290 (651) - True up of tax returns 11,029 - (356,095) Tax loss expired and other 21,823 - 950 - - -
Schedule of Deferred Tax Assets and Liabilities	November 30, November 30, November 30, 2018 2017 2016 $ $ $ Deferred tax assets Non-capital loss carry-forwards 11,847,710 8,972,285 7,427,516 Book and tax basis differences on assets and liabilities 1,041,360 863,215 3,409,343 Other 2,586,070 2,681,375 - Investment tax credit 3,354,760 2,865,404 2,405,365 Undeducted research and development expenditures 4,870,130 4,158,178 3,710,274 Capital loss carryforwards 326,060 326,064 - Share issuance cost 1,152,750 436,427 - Net operating loss carryforwards - 14,135 - 25,178,840 20,317,083 16,952,498 Valuation allowances for deferred tax assets (25,178,840) (20,317,083) (16,952,498) Net deferred tax assets - - -
Schedule of Operating Losses	Canadian income tax losses expiring in the year ended November 30, Federal $ 2028 182,222 2029 555,539 2030 3,373,079 2031 5,532,739 2032 5,750,053 2033 4,562,538 2034 149,927 2035 2,634,823 2036 5,341,606 2037 5,694,760 2038 10,931,052 44,708,338

Note 17 - Financial Instrumen_2

Note 17 - Financial Instruments (Tables)	12 Months Ended
	Nov. 30, 2018
Disclosure Text Block Supplement [Abstract]
Fair Value Measurements, Nonrecurring	November 30, 2018 November 30, 2017 Carrying Fair Carrying Fair amount value amount value $ $ $ $ Financial Liabilities Convertible debentures (i) 1,790,358 1,795,796 1,290,465 1,316,386
Past Due Financing Receivables	November 30, November 30, 2018 2017 $ $ Total accounts receivable 305,912 756,468 Less allowance for doubtful accounts (66,849) (66,849) Total accounts receivable, net 239,063 689,619 Not past due 239,063 689,619 Past due for more than 31 days but no more than 120 days - 5,176 Past due for more than 120 days 66,849 61,673 Total accounts receivable, gross 305,912 756,468
Contractual Obligation, Fiscal Year Maturity Schedule	Less than 3 to 6 6 to 9 9 months Greater than 3 months months months to 1 year 1 year Total $ $ $ $ $ $ Third parties Accounts payable 2,643,437 - - - - 2,643,437 Accrued liabilities 353,147 - - - - 353,147 Related parties Employee costs payable 222,478 - - - - 222,478 Convertible debentures (Note 7) 52,274 1,376,805 12,603 12,466 537,808 1,991,956 3,271,336 1,376,805 12,603 12,466 537,808 5,211,018

Note 18 - Segmented Informati_2

Note 18 - Segmented Information (Tables)	12 Months Ended
	Nov. 30, 2018
Segment Reporting [Abstract]
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	November 30, November 30, November 30, 2018 2017 2016 $ $ $ Revenue United States 1,712,731 5,504,452 2,247,002 1,712,731 5,504,452 2,247,002 Total assets Canada 11,474,227 7,396,781 7,974,689 Total property and equipment Canada 2,755,993 3,267,551 1,889,638

Note 1 - Nature of Operations (

Note 1 - Nature of Operations (Details Narrative) - CAD ($)	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2016
Disclosure Text Block [Abstract]
Net Loss Attributable to Parent	$ (13,747,480)	$ (8,857,440)	$ (10,143,577)
Accumulated Deficit	$ (85,620,939)	$ (71,873,459)

Note 3 - Significant Accounti_4

Note 3 - Significant Accounting Policies (Details)	12 Months Ended
	Nov. 30, 2018
Declining Balance [Member] | Computer Equipment [Member]
Note 3 - Significant Accounting Policies (Details) - Depreciation Rates [Line Items]
Declining Balance Depreciation Rate	30.00%
Declining Balance [Member] | Computer Software, Intangible Asset [Member]
Note 3 - Significant Accounting Policies (Details) - Depreciation Rates [Line Items]
Declining Balance Depreciation Rate	50.00%
Declining Balance [Member] | Furniture and Fixtures [Member]
Note 3 - Significant Accounting Policies (Details) - Depreciation Rates [Line Items]
Declining Balance Depreciation Rate	20.00%
Declining Balance [Member] | Laboratory Equipment [Member]
Note 3 - Significant Accounting Policies (Details) - Depreciation Rates [Line Items]
Declining Balance Depreciation Rate	20.00%
Straight Line [Member] | Leasehold Improvements [Member]
Note 3 - Significant Accounting Policies (Details) - Depreciation Rates [Line Items]
Leasehold improvements	Over term of lease

Note 3 - Significant Accounti_5

Note 3 - Significant Accounting Policies (Details Narrative) - CAD ($)	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2016
Accounting Policies [Abstract]
Deferred revenue	$ 2,362,500	$ 2,662,500
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)	22,540,535	980,791	754,027

Note 4 - Accounts Receivable (D

Note 4 - Accounts Receivable (Details Narrative) - CAD ($)	Nov. 30, 2018	Nov. 30, 2017
Note 4 - Accounts Receivable
Account receivable	$ 305,912	$ 756,468
Allowance for doubtful accounts	$ 66,849	$ 66,849

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment (Details) - CAD ($)	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017
Cost, beginning balance	$ 7,940,320	$ 6,041,569
Additions	101,178	1,898,751
Cost, ending balance	8,041,498	7,940,320
Accumulated amortization, beginning balance	4,672,769	4,151,931
Depreciation	612,736	520,838
Accumulated amortization, ending balance	5,285,505	4,672,769
Net book value	2,755,993	3,267,551
Computer Equipment [Member]
Cost, beginning balance	530,750	295,296
Additions	20,336	235,454
Cost, ending balance	551,086	530,750
Accumulated amortization, beginning balance	286,483	238,672
Depreciation	77,179	47,811
Accumulated amortization, ending balance	363,662	286,483
Net book value	187,424	244,267
Computer Software [Member]
Cost, beginning balance	156,059	124,151
Additions	0	31,908
Cost, ending balance	156,059	156,059
Accumulated amortization, beginning balance	131,128	117,506
Depreciation	12,465	13,622
Accumulated amortization, ending balance	143,593	131,128
Net book value	12,466	24,931
Furniture and Fixtures [Member]
Cost, beginning balance	172,498	129,860
Additions	0	42,638
Cost, ending balance	172,498	172,498
Accumulated amortization, beginning balance	119,990	109,243
Depreciation	10,501	10,747
Accumulated amortization, ending balance	130,491	119,990
Net book value	42,007	52,508
Laboratory Equipment [Member]
Cost, beginning balance	5,286,803	3,933,693
Additions	80,842	1,353,110
Cost, ending balance	5,367,645	5,286,803
Accumulated amortization, beginning balance	2,669,232	2,290,074
Depreciation	413,576	379,158
Accumulated amortization, ending balance	3,082,808	2,669,232
Net book value	2,284,837	2,617,571
Leasehold Improvements [Member]
Cost, beginning balance	1,441,452	1,205,811
Additions	0	235,641
Cost, ending balance	1,441,452	1,441,452
Accumulated amortization, beginning balance	1,192,946	1,143,792
Depreciation	82,835	49,154
Accumulated amortization, ending balance	1,275,781	1,192,946
Net book value	165,671	248,506
Laboratory Equipment Under Capital Lease [Member]
Cost, beginning balance	276,300	276,300
Additions	0	0
Cost, ending balance	276,300	276,300
Accumulated amortization, beginning balance	198,798	179,422
Depreciation	15,500	19,376
Accumulated amortization, ending balance	214,298	198,798
Net book value	62,002	77,502
Computer Equipment Under Capital Lease [Member]
Cost, beginning balance	76,458	76,458
Additions	0	0
Cost, ending balance	76,458	76,458
Accumulated amortization, beginning balance	74,192	73,222
Depreciation	680	970
Accumulated amortization, ending balance	74,872	74,192
Net book value	$ 1,586	$ 2,266

Note 5 - Property and Equipme_4

Note 5 - Property and Equipment (Details Narrative) - CAD ($)	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2016
Property, Plant and Equipment [Abstract]
Depreciation	$ 612,736	$ 520,838	$ 385,210
Depreciation expense within cost of goods sold	$ 2,352	$ 13,877	$ 0

Note 6 - Accrued Liabilities (D

Note 6 - Accrued Liabilities (Details) - CAD ($)	Nov. 30, 2018	Nov. 30, 2017
Accrued Liabilities [Abstract]
Professional fees	$ 229,170	$ 400,796
Property taxes	0	111,970
Interest	17,413	54,110
Other	106,564	215,493
Accrued liabilities	$ 353,147	$ 782,369

Note 7 - Due to Related Parti_3

Note 7 - Due to Related Parties (Details) - CAD ($)	Nov. 30, 2018	Nov. 30, 2017
Amounts Due to Related Parties [Abstract]
Convertible debenture payable to two directors and officers of the Company, unsecured, 12% annual interest rate, payable monthly (“2013 Debenture”)	$ 1,350,000	$ 1,290,465
Convertible debenture payable to two directors and officers of the Company, unsecured, 10% annual interest rate, Payable monthly (“2018 Debenture”)	440,358	0
Due to Related Parties	$ 1,790,358	$ 1,290,465

Note 7 - Due to Related Parti_4

Note 7 - Due to Related Parties (Details Narrative) - CAD ($)	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2016
Related Party Transactions [Abstract]
Accretion Expense	$ 66,560	$ 219,497	$ 79,245
Coupon interest on the Debentures	$ 172,977	$ 162,530	$ 180,370

Note 8 - Employee Costs Payab_2

Note 8 - Employee Costs Payable (Details Narrative) - CAD ($)	Nov. 30, 2018	Nov. 30, 2017
Compensation Related Costs [Abstract]
Employee-related Liabilities, Current	$ 222,478	$ 214,980

Note 9 - Lease Obligations (Det

Note 9 - Lease Obligations (Details)	Nov. 30, 2018CAD ($)
Minimum Lease Payments [Abstract]
2,019	$ 180,436
2,020	180,436
Balance, long-term portion	$ 360,872

Note 10 - Capital Stock (Detail

Note 10 - Capital Stock (Details Narrative) - CAD ($)	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2016
Note 10 - Capital Stock (Details) [Line Items]
Common Stock, Shares, Issued (in Shares)	18,252,243	3,470,451	29,789,992
Common Stock, Shares, Outstanding (in Shares)	18,252,243	3,470,451	29,789,992
Proceeds From Issuance Or Sale Of Equity Net Of Issuance Costs	$ 0	$ 2,468,474	$ 3,368,674
Odidi Holdco [Member]
Note 10 - Capital Stock (Details) [Line Items]
Common Stock, Shares, Issued (in Shares)		5,781,312	5,781,312
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	3.00%	17.00%	19.00%

Note 11 - Options (Details)

Note 11 - Options (Details) - $ / shares	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2016
Fair Value Assumptions of Option Awards [Abstract]
Volatility	0.00%	71.70%	65.20%
Risk-free interest rate	0.00%	1.56%	0.62%
Expected life (in years)		5 years 5 months 26 days	5 years
Dividend yield	0.00%	0.00%	0.00%
The weighted average grant date fair value per options granted (in Dollars per share)	$ 0	$ 7.50	$ 12

Note 11 - Options (Details 1)

Note 11 - Options (Details 1) - $ / shares	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2016
Stock Option Transactions [Abstract]
Outstanding, beginning of period, (in Shares)	582,811	539,246	506,200
Granted (in Shares)		49,600	46,000
Exercised (in Shares)		(200)	2,750
Forfeiture (in Shares)	(25,533)
Expired (in Shares)	1,627	5,835	10,204
Balance at end of period (in Shares)	555,651	582,811	539,246
Options exercisable, end of year (in Shares)	544,619	522,106	439,661
Outstanding, beginning of period,	$ 32	$ 34.80	$ 38.90
Granted	0	11.70	24.20
Exercised	0	23.20	25.70
Forfeiture	20.36
Expired	291.07	126.40	192.40
Balance at end of period	31.75	32	34.80
Options exercisable, end of year	32.16	33	34.90
Outstanding, beginning of period,	17.20	18.80	22.10
Granted	0	7.50	12
Exercised	0	12	16.80
Forfeiture	14.19	0	0
Expired	228.92	96	132.90
Balance at end of period	16.69	17.20	18.80
Options exercisable, end of year	$ 16.91	$ 17.90	$ 19.60

Note 11 - Options (Details 2)

Note 11 - Options (Details 2) - $ / shares	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2016
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding (in Shares)	555,651
Weighted average exercise price per share	$ 31.75
Number exercisable (in Shares)	544,619	522,106	439,661
Weighted average exercise price per share	$ 32.16	$ 33	$ 34.90
Weighted average grant date fair value	16.91	$ 17.90	$ 19.60
Range 1 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, upper limit	$ 25
Number outstanding (in Shares)	109,067
Weighted average exercise price per share	$ 17.99
Weighted average remaining contract life (years)	2 years 7 months 28 days
Weighted average grant date fair value	$ 9.75
Number exercisable (in Shares)	98,035
Weighted average exercise price per share	$ 14.14
Weighted average grant date fair value	10.15
Range 2 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower limit	25
Exercise price range, upper limit	$ 26
Number outstanding (in Shares)	446,584
Weighted average exercise price per share	$ 35.11
Weighted average remaining contract life (years)	1 year 11 months 23 days
Weighted average grant date fair value	$ 29.25
Number exercisable (in Shares)	446,584
Weighted average exercise price per share	$ 35.11
Weighted average grant date fair value	$ 29.25

Note 11 - Options (Details 3)

Note 11 - Options (Details 3) - CAD ($)	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation expense components	$ 927,686	$ 1,749,999	$ 2,261,444
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation expense components	883,064	1,654,051	1,995,805
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation expense components	$ 44,622	$ 95,948	$ 265,639

Note 11 - Options (Details Narr

Note 11 - Options (Details Narrative) - CAD ($)	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		49,600	46,000
Allocated Share-based Compensation Expense (in Dollars)	$ 927,686	$ 1,749,999	$ 2,261,444
Proceeds from Stock Options Exercised (in Dollars)	$ 0	$ 1,742	$ 52,868
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		200	(2,750)
Stock Option Sharebased Compensation Forfeiture Rate	4.00%	4.00%	4.00%

Note 12 - Deferred Share Unit_2

Note 12 - Deferred Share Units (Details) - Deferred Share Units [Member] - CAD ($)	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2016
Note 12 - Deferred Share Units (Details) - Deferred Share Units [Line Items]
Additional paid in capital	$ 7,565	$ 30,355	$ 31,628
Additional paid in capital	866	1,738	1,674
Accrued liability	$ 0	$ 7,562	$ 7,261
Accrued liability	0	866	235

Note 12 - Deferred Share Unit_3

Note 12 - Deferred Share Units (Details Narrative) - shares	Nov. 30, 2018	Nov. 30, 2017
Deferred Share Units [Member]
Note 12 - Deferred Share Units (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	10,279	9,413

Note 14 - Warrants (Details)

Note 14 - Warrants (Details) - $ / shares	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017
Class of Warrant or Right [Line Items]
Number Outstanding	26,533,624	714,045
Shares Issuable Upon Exercise	26,394,885
June 2016 Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share)	$ 19.30
Number Outstanding	277,478	277,872
Expiry	Jun. 2, 2021
Shares Issuable Upon Exercise	138,739
October 2017 Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share)	$ 12.50
Number Outstanding	181,818	181,818
Expiry	Oct. 13, 2020
Shares Issuable Upon Exercise	181,818
October 2017 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share)	$ 13.750
Number Outstanding	18,181
Expiry	Oct. 13, 2020
Shares Issuable Upon Exercise	18,181
March 2018 Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share)	$ 6
Expiry	Mar. 16, 2021
Shares Issuable Upon Exercise	291,666
March 2018 Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share)	$ 6
Number Outstanding	150,000
Expiry	Mar. 21, 2021
Shares Issuable Upon Exercise	150,000
March 2018 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share)	$ 7.50
Number Outstanding	29,166
Expiry	Mar. 16, 2021
Shares Issuable Upon Exercise	29,166
March 2018 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share)	$ 7.50
Number Outstanding	15,000
Expiry	Mar. 21, 2021
Shares Issuable Upon Exercise	15,000
2018 Firm Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share)	$ 0.75
Number Outstanding	20,000,000
Expiry	Oct. 16, 2023
Shares Issuable Upon Exercise	20,000,000
2018 Pre-Funded Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share)	$ 0.01
Number Outstanding	4,410,001	0
Expiry	Oct. 16, 2023
Shares Issuable Upon Exercise	4,410,001
October 2018 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share)	$ 0.9375
Number Outstanding	1,160,314	0
Expiry	Oct. 16, 2023
Shares Issuable Upon Exercise	1,160,314

Note 14 - Warrants (Details 1)

Note 14 - Warrants (Details 1)	12 Months Ended
	Nov. 30, 2018shares
Note 14 - Warrants (Details) - Warrant Transactions [Line Items]
Outstanding, Beginning	714,045
Issued	38,209,481
Expired	(236,174)
Exercised	(12,153,334)
Rounding on consolidation	(394)
Outstanding, Ending	26,533,624
March 2013 Warrants [Member]
Note 14 - Warrants (Details) - Warrant Transactions [Line Items]
Outstanding, Beginning	149,174
Issued	0
Expired	(149,174)
Exercised	0
Rounding on consolidation	0
Outstanding, Ending	0
July 2013 Warrants [Member]
Note 14 - Warrants (Details) - Warrant Transactions [Line Items]
Outstanding, Beginning	87,000
Issued	0
Expired	(87,000)
Exercised	0
Rounding on consolidation	0
Outstanding, Ending	0
June 2016 Warrants [Member]
Note 14 - Warrants (Details) - Warrant Transactions [Line Items]
Outstanding, Beginning	277,872
Issued	0
Expired	0
Exercised	0
Rounding on consolidation	(394)
Outstanding, Ending	277,478
October 2017 Warrants [Member]
Note 14 - Warrants (Details) - Warrant Transactions [Line Items]
Outstanding, Beginning	181,818
Issued	0
Expired	0
Exercised	0
Rounding on consolidation	0
Outstanding, Ending	181,818
October 2017 Placement Agent Warrants [Member]
Note 14 - Warrants (Details) - Warrant Transactions [Line Items]
Outstanding, Beginning	18,181
Issued	0
Expired	0
Exercised	0
Rounding on consolidation	0
Outstanding, Ending	18,181
March 2018 Warrants [Member]
Note 14 - Warrants (Details) - Warrant Transactions [Line Items]
Outstanding, Beginning	0
Issued	441,666
Expired	0
Exercised	0
Rounding on consolidation	0
Outstanding, Ending	441,666
March 2018 Placement Agent Warrants [Member]
Note 14 - Warrants (Details) - Warrant Transactions [Line Items]
Outstanding, Beginning	0
Issued	44,166
Expired	0
Exercised	0
Rounding on consolidation	0
Outstanding, Ending	44,166
2018 Firm Warrants[Member]
Note 14 - Warrants (Details) - Warrant Transactions [Line Items]
Outstanding, Beginning	0
Issued	20,000,000
Expired	0
Exercised	0
Rounding on consolidation	0
Outstanding, Ending	20,000,000
2018 Pre-Funded Warrants [Member]
Note 14 - Warrants (Details) - Warrant Transactions [Line Items]
Outstanding, Beginning	0
Issued	16,563,335
Expired	0
Exercised	(12,153,334)
Rounding on consolidation	0
Outstanding, Ending	4,410,001
October 2018 Placement Agent Warrants [Member]
Note 14 - Warrants (Details) - Warrant Transactions [Line Items]
Outstanding, Beginning	0
Issued	1,160,314
Expired	0
Exercised	0
Rounding on consolidation	0
Outstanding, Ending	1,160,314

Note 14 - Warrants (Details Nar

Note 14 - Warrants (Details Narrative) - CAD ($)	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2016
Note 14 - Warrants (Details) [Line Items]
Issuance of Shares on Exercise of Warrants (in Dollars)	$ 0	$ 324,258	$ 700,653
Additional Paid-in Capital [Member]
Note 14 - Warrants (Details) [Line Items]
Issuance of Shares on Exercise of Warrants (in Dollars)	$ 0	$ (106,315)	$ (330,066)
Cash Exercise Of Warrants [Member]
Note 14 - Warrants (Details) [Line Items]
Warrants Exercised	0	33,601	83,210
Stock Issued During Period, Shares, Conversion of Convertible Securities	0	16,801	35,791

Note 15 - Income Taxes (Details

Note 15 - Income Taxes (Details) - CAD ($)	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2016
Income Tax Reconciliation [Abstract]
Statutory income tax rate	26.50%	26.50%	26.50%
Statutory income tax recovery	$ (3,643,080)	$ (2,347,222)	$ (2,688,048)
Increase (decrease) in income taxes
Non-deductible expenses/ non-taxable income	263,650	488,769	640,481
Change in valuation allowance	4,861,770	2,128,819	2,683,775
Investment tax credit	(466,052)	0	0
Financing costs booked to equity	(1,049,430)	(269,715)	281,063
Difference in foreign tax rates	290	(651)	0
True up of tax returns	11,029	0	(356,095)
Tax loss expired, etc	21,823	0	950
Income Tax Expense/Benefit	$ 0	$ 0	$ 0

Note 15 - Income Taxes (Detai_2

Note 15 - Income Taxes (Details 1) - CAD ($)	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2016
Deferred tax assets
Non-capital loss carry-forwards	$ 11,847,710	$ 8,972,285	$ 7,427,516
Book and tax basis differences on assets and liabilities	1,041,360	863,215	3,409,343
Other	2,586,070	2,681,375	0
Investment tax credit	3,354,760	2,865,404	2,405,365
Undeducted research and development expenditures	4,870,130	4,158,178	3,710,274
Capital loss carryforwards	326,060	326,064	0
Share issuance cost	1,152,750	436,427	0
Net operating loss carryforwards	0	14,135	0
Gross deferred tax assets	25,178,840	20,317,083	16,952,498
Valuation allowances for deferred tax assets	(25,178,840)	(20,317,083)	(16,952,498)
Net deferred tax assets	$ 0	$ 0	$ 0

Note 15 - Income Taxes (Detai_3

Note 15 - Income Taxes (Details 2) - Canada [Member]	Nov. 30, 2018CAD ($)
Note 15 - Income Taxes (Details) - Summary of Operating Losses [Line Items]
Income tax losses expiring in the year	$ 44,708,338
Tax Loss Expiration 2028 [Member]
Note 15 - Income Taxes (Details) - Summary of Operating Losses [Line Items]
Income tax losses expiring in the year	182,222
Tax Loss Expiration 2029 [Member]
Note 15 - Income Taxes (Details) - Summary of Operating Losses [Line Items]
Income tax losses expiring in the year	555,539
Tax Loss Expiration 2030 [Member]
Note 15 - Income Taxes (Details) - Summary of Operating Losses [Line Items]
Income tax losses expiring in the year	3,373,079
Tax Loss Expiration 2031 [Member]
Note 15 - Income Taxes (Details) - Summary of Operating Losses [Line Items]
Income tax losses expiring in the year	5,532,739
Tax Loss Expiration 2032 [Member]
Note 15 - Income Taxes (Details) - Summary of Operating Losses [Line Items]
Income tax losses expiring in the year	5,750,053
Tax Loss Expiration 2033 [Member]
Note 15 - Income Taxes (Details) - Summary of Operating Losses [Line Items]
Income tax losses expiring in the year	4,562,538
Tax Loss Expiration 2034 [Member]
Note 15 - Income Taxes (Details) - Summary of Operating Losses [Line Items]
Income tax losses expiring in the year	149,927
Tax Loss Expiration 2035 [Member]
Note 15 - Income Taxes (Details) - Summary of Operating Losses [Line Items]
Income tax losses expiring in the year	2,634,823
Tax Loss Expiration 2036 [Member]
Note 15 - Income Taxes (Details) - Summary of Operating Losses [Line Items]
Income tax losses expiring in the year	5,341,606
Tax Loss Expiration 2037 [Member]
Note 15 - Income Taxes (Details) - Summary of Operating Losses [Line Items]
Income tax losses expiring in the year	5,694,760
Tax Loss Expiration 2038 [Member]
Note 15 - Income Taxes (Details) - Summary of Operating Losses [Line Items]
Income tax losses expiring in the year	$ 10,931,052

Note 15 - Income Taxes (Detai_4

Note 15 - Income Taxes (Details Narrative) - CAD ($)	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2016
Income Tax Disclosure [Abstract]
Tax Credit Carryforward, Amount	$ 998,849	$ 636,489	$ 681,136
Income Tax Expense Benefit	0	0	0
Unrecognized Tax Benefits, Income Tax Penalties Expense	0	0	0
Unrecognized Tax Benefits, Interest on Income Taxes Accrued	0	0	0
Unrecognized Tax Benefits	$ 0	$ 0	$ 0

Note 17 - Financial Instrumen_3

Note 17 - Financial Instruments (Details) - CAD ($)	Nov. 30, 2018	Nov. 30, 2017
Financial Liabilities
Convertible debentures, carrying amount	$ 1,790,358	$ 1,290,465
Convertible debentures, fair value	$ 1,795,796	$ 1,316,386

Note 17 - Financial Instrumen_4

Note 17 - Financial Instruments (Details 1) - CAD ($)	Nov. 30, 2018	Nov. 30, 2017
Financing Receivable, Recorded Investment, Past Due [Line Items]
Total accounts receivable	$ 305,912	$ 756,468
Less allowance for doubtful accounts	(66,849)	(66,849)
Total accounts receivable, net	239,063	689,619
Not past due	239,063	689,619
Past due	305,912	756,468
Financing Receivables 31 To 120 Days Past Due [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Past due	0	5,176
Financing Receivables More Than 120 Days Past Due [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Past due	$ 66,849	$ 61,673

Note 17 - Financial Instrumen_5

Note 17 - Financial Instruments (Details 2)	12 Months Ended
	Nov. 30, 2018CAD ($)
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Undiscounted future cash flows	$ 5,211,018
Less Than 3 Months [Member]
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Undiscounted future cash flows	3,271,336
Three To Six Months [Member]
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Undiscounted future cash flows	1,376,805
Six To Nine Months [Member]
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Undiscounted future cash flows	12,603
Nine Months To One Year [Member]
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Undiscounted future cash flows	12,466
Greater Than One Year [Member]
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Undiscounted future cash flows	537,808
Accounts Payable [Member]
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Third parties	2,643,437
Accounts Payable [Member] | Less Than 3 Months [Member]
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Third parties	2,643,437
Accounts Payable [Member] | Three To Six Months [Member]
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Third parties	0
Accounts Payable [Member] | Six To Nine Months [Member]
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Third parties	0
Accounts Payable [Member] | Nine Months To One Year [Member]
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Third parties	0
Accounts Payable [Member] | Greater Than One Year [Member]
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Third parties	0
Accrued Liabilities [Member]
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Third parties	353,147
Accrued Liabilities [Member] | Less Than 3 Months [Member]
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Third parties	353,147
Accrued Liabilities [Member] | Three To Six Months [Member]
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Third parties	0
Accrued Liabilities [Member] | Six To Nine Months [Member]
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Third parties	0
Accrued Liabilities [Member] | Nine Months To One Year [Member]
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Third parties	0
Accrued Liabilities [Member] | Greater Than One Year [Member]
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Third parties	0
Employee Costs Payable [Member]
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Related parties	222,478
Employee Costs Payable [Member] | Less Than 3 Months [Member]
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Related parties	222,478
Employee Costs Payable [Member] | Three To Six Months [Member]
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Related parties	0
Employee Costs Payable [Member] | Six To Nine Months [Member]
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Related parties	0
Employee Costs Payable [Member] | Nine Months To One Year [Member]
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Related parties	0
Employee Costs Payable [Member] | Greater Than One Year [Member]
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Related parties	0
Unsecured Convertible Debentures [Member]
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Related parties	1,991,956
Unsecured Convertible Debentures [Member] | Less Than 3 Months [Member]
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Related parties	52,274
Unsecured Convertible Debentures [Member] | Three To Six Months [Member]
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Related parties	1,376,805
Unsecured Convertible Debentures [Member] | Six To Nine Months [Member]
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Related parties	12,603
Unsecured Convertible Debentures [Member] | Nine Months To One Year [Member]
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Related parties	12,466
Unsecured Convertible Debentures [Member] | Greater Than One Year [Member]
Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities [Line Items]
Related parties	$ 537,808

Note 18 - Segmented Informati_3

Note 18 - Segmented Information (Details) - CAD ($)	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2016
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 1,712,731	$ 5,504,452	$ 2,247,002
Assets	11,474,227	7,396,781
Total property and equipment	2,755,993	3,267,551
CANADA
Revenues from External Customers and Long-Lived Assets [Line Items]
Assets	11,474,227	7,396,781	7,974,689
Total property and equipment	$ 2,755,993	$ 3,267,551	$ 1,889,638